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Randomized controlled trials (RCTs) are widely considered the gold standard to 
assess the effectiveness of new treatments. Decisions for clinical guidelines and 
health policies are often made based on findings of RCTs. While study designs of 
RCTs can mitigate threats to internal validity of the estimated treatment 
effectiveness, they do not assure external validity, which is how well findings 
from one particular sample can be applied to the target population of individuals 
for whom a treatment is intended. There is growing concern in the recent 
literature that the findings from RCTs may not be directly applicable to real world 
settings. Particularly in the context of RCTs of treatments for substance use 
disorders (SUD), there is a growing body of literature showing that strict eligibility 
criteria commonly used in RCTs of SUD treatment would exclude substantial 
proportions of individuals from the target population, which may adversely impact 
generalizability of the findings from SUD RCTs. However, very few past studies 
have assessed generalizability of findings of actual SUD RCTs to the intended 
target populations. The purpose of this dissertation was to assess generalizability 
of findings of SUD RCTs that were implemented in various settings, as compared 
with differently defined target populations. In Chapter 1, we provided an overview 
of the existing literature and described the data source and methodology used in 
this dissertation. In Chapter 2, we assessed generalizability of the findings from 
ten multi-site SUD RCTs to each target population of patients seeking SUD 
treatment in usual treatment settings in the United States. We weighted the RCT 
sample treatment effects on three outcomes, on retention, urine toxicology, and 
abstinence to make the RCT samples resemble the target populations, by using 
propensity scores representing the conditional probability of participating in 
RCTs. We found that weighting the samples changed the significance of 
estimated sample treatment effects. Most commonly, positive treatment effects of 
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RCTs became statistically insignificant after weighting. In Chapter 3, we 
assessed generalizability of the treatment effects on retention and abstinence 
from a multi-site web-based SUD intervention to two types of target populations: 
SUD treatment-seeking individuals and community-dwelling individuals with 
recent substance use, whether or not they sought treatment. The population 
effect on abstinence became insignificant after weighting the data by the 
generalizability weights of both target populations. In Chapter 4, we conducted a 
meta-analysis of generalized treatment effects on retention and abstinence from 
four RCTs of cocaine dependence treatments to the same two types of target 
population used in the previous chapter. We also conducted a network meta-
analysis to examine comparative treatment efficacies across these four 
treatments while taking into account the generalizability of the findings. We found 
that the overall generalized treatment effect on retention was significantly larger 
than the unweighted effect. We also found that weighting changed the ranking of 
the effectiveness across treatments. Lastly, in Chapter 5, we provided a 
summary of the findings and discussed public health implications in light of 
strengths and limitations of this dissertation.  
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CHAPTER 1 Introduction 
1.1. Background 
Randomized controlled trials (RCTs) are generally considered the most reliable 
study design for evaluating the effectiveness of new treatments and 
interventions. Directions for treatment guidelines and health policies are often 
made based on findings of RCTs. Moreover, RCTs provide the most reliable 
causal inferences of the effects of new treatments and interventions by mitigating 
threats to internal validity. However, the study design of RCTs does not assure 
external validity, which is how well findings from one particular sample can be 
applied to the target population of individuals for whom a treatment or an 
intervention is intended.  
There is growing concern in the recent literature that the findings from 
RCTs may not be directly applicable to real world settings.1–6 The findings of an 
intervention with strong treatment effects in one particular setting often cannot be 
replicated or produce smaller effects in different settings.7,8 Particularly in the 
context of RCTs of treatments for substance use disorders (SUD), there is a 
growing body of study findings showing that the characteristics of RCT samples 
differ substantially from those of target populations.2,9,10 It has been found that 
women, especially pregnant women, African-Americans, individuals with lower 
income, and individuals with more severe substance use or psychiatric problems 
are under-represented in the RCTs for SUD treatments.9,10 Additionally, it has 
been found that eligibility criteria commonly used in RCTs of SUD treatment 
exclude substantial proportions of individuals from the target population. 
According to Humphrey et al.,9 20% to 33% of individuals with alcohol use 
disorders would be excluded by the commonly used eligibility criteria in RCTs of 
alcohol use disorders. Another study by Okuda et al.2  found that 80% of 
individuals with cannabis dependence would be excluded by the commonly used 
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eligibility criteria for cannabis treatment RCTs. Moreover, a recent review study 
by Moberg and Humphreys11 estimated that commonly used exclusion criteria in 
SUD trials would exclude between 64% and 95% of potential participants. A 
more recent study by Susukida et al.12 found that the participants of the SUD 
RCTs were more likely to have higher level of educational attainment and have 
full time jobs as compared with the individuals seeking SUD treatment in usual 
treatment setting.  
While using less stringent eligibility criteria to improve the 
representativeness of RCTs may be a straightforward solution, concerns for non-
adherence with treatment, and patient safety often prevent researchers from 
expanding eligibility criteria of RCTs. Furthermore, there is some evidence that 
the eligibility criteria of SUD treatment RCTs have become more stringent over 
the recent years.13 Particularly, SUD RCTs funded by government tend to use 
such restrictive eligibility criteria.13 In order to assess generalizability of the 
findings of RCTs, it is important to examine how representative the RCT samples 
are of potential target populations, and whether and how lack of 
representativeness might have affected the findings of RCTs.14  
While most previous studies have examined what proportion of a putative 
target population would be hypothetically excluded from RCTs, very few studies 
with a few recent exceptions have compared the characteristics of actual RCT 
participants and the target populations to assess representativeness of the RCT 
samples. Also, few studies have examined whether and how representativeness 
of the RCT sample may affect the findings of the RCTs when generalized to a 
target population. Furthermore, there is little understanding of how 
generalizability of the findings of RCTs differ depending on the definitions of the 
target populations. For instance, the target population for the RCT for alcohol use 
disorder could be defined as individuals who are seeking treatment for alcohol 
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use disorder or could be defined as individuals with alcohol use disorder 
regardless of treatment seeking status. Particularly in the context of SUD, there 
is a large proportion of individuals with SUD who do not receive treatment 
despite their treatment needs. Hence, it is important to assess whether treatment 
effects estimated through SUD RCTs can be applicable to those with SUD 
regardless of treatment seeking status. Finally, there is increasing interest in 
assessing comparative treatment efficacies by comparing different treatments 
from different RCTs; however, no previous studies assessed comparative 
treatment efficacies taking into account generalizability of the RCTs to the target 
populations. This dissertation aimed to address these issues by using the data 
from SUD RCTs that were actually implemented in various settings.  
 
1.2. Significance  
Concerns for limited generalizability of the findings from RCTs 
RCTs are widely considered the gold standard to assess efficacy of new 
interventions since the first introduction of this study design in the early 20th 
century. RCTs provide confidence that the estimated treatment effects are 
actually caused by new interventions. Despite its strength in assuring internal 
validity, the study design of RCTs does not necessarily assure external validity, 
which is how well findings from one particular setting can be applied to the target 
population for whom an intervention is intended.  
In social science and medical fields, assuring generalizability of the findings 
from RCTs is more critical than in physical sciences where typically humans are 
not involved because humans react to new interventions or treatments differently 
based on their genetic predispositions and environmental factors including socio-
economic status and cultures. Decisions regarding implementation and 
dissemination of new interventions and treatments should be made based on not 
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only the observed effects from RCTs but also the external validity of the 
observed effects to the intended target populations.  
While many efforts to recruit RCT participants from real-world settings have 
been made to improve generalizability of the findings from RCTs,15 there are 
certain obstacles that often make these efforts unsuccessful. For example, many 
people who are recruited to the RCTs decide not to participate. Those who 
participate in RCTs willingly may differ in terms of attitude toward treatments or 
interventions and socio-demographic status from those who refuse to participate 
in RCTs. The treatment effects estimated with only those who agreed to 
participate in RCTs may not be necessarily generalizable to those who refused to 
participate in RCTs, who may have responded to treatment differently. Refusal to 
participate in RCTs is particularly concerning in the context of SUD treatments 
because a large proportion of patients are referred to treatment through legal 
authorities such as criminal justice and are not seeking treatment voluntarily. 
Stringent eligibility criteria of many RCTs often limits ability to include 
representative samples from broad target populations.2,10,16 A review study of 41 
NIH sponsored RCTs in various fields demonstrated that approximately 73% of a 
representative sample was excluded from these studies due to commonly used 
eligibility criteria.17 In the literature on RCTs for SUD treatments, use of restrictive 
eligibility criteria is one of the major concerns for limited generalizability of the 
findings from RCTs to target populations. For instance, one study estimated that 
common eligibility criteria in cannabis treatment RCTs would exclude almost 80% 
of patients with cannabis treatment.2  
While relaxing eligibility criteria may seem to be the most straightforward 
solution to make RCT samples more representative, it may not be always 
feasible for all RCTs, especially when there are safety concerns for patients. For 
example, co-existing medical conditions may make participation in RCTs of a 
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new treatment difficult, especially if the treatment includes use of novel 
medications which could interact with the medications that the potential RCT 
participant is already taking. In such cases where relaxing eligibility criteria is 
challenging, it is important for researchers to have useful tools to examine to 
what extent the findings of RCTs are applicable to target populations. This 
dissertation applies a novel weighting-based method to various SUD RCTs to 
assess the sample representativeness and the generalizability of the RCT 
findings to intended target populations.  
 
 
Limited sample representativeness of SUD RCTs 
Many RCTs of SUD treatments tend to exclude those with co-occurring medical 
and psychiatric disorders.11 While some eligibility criteria are reasonable to 
ensure safety of RCT participants, some criteria are used merely for logistic 
convenience such as excluding those without stable housing, and some criteria 
are not based on a clear rationale.18 There is a growing interest in whether and 
how the eligibility criteria for SUD RCTs impact the sample representativeness 
and external validity of the findings from RCTs.11  
A review by Humphreys et al.13 identified 14 eligibility criteria that are most 
commonly used in alcohol treatment research (683 studies): alcohol problems 
(39.1%), psychiatric problems (37.8%), prior alcohol treatment (31.8%), medical 
conditions (31.6%), compliance/motivation (31.5%), demographic (26.2%), 
neurocognitive problems (23.0%), illicit drug use (22.7%), social instability 
(14.9%), distance from treatment (10.1%), residential stability (8.6%), 
education/literacy (4.4%), legal problems (3.5%), and financial situation (1.3%).  
Blanco et al.19 found that the set of criteria identified by Humphreys et al.13 
excluded 50.5% of representative individuals with alcohol dependence in the US 
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and 79.4% of those who actually sought treatment for alcohol dependence, by 
using the National Epidemiologic Survey on Alcohol and Related Conditions 
(NESARC) data. Using the NESARC data of those with alcohol dependence, 
Hoertel et al.20 found that 64.3% of those with co-occurring mood disorder were 
excluded with Humphreys-identified criteria.13 Similarly, Storbjork21 found that at 
least one of the 14 criteria by Humphreys et al.13 excluded 96% of representative 
individuals with alcohol dependence who were seeking treatment in Stockholm 
County, Sweden. Okuda et al.22 conducted a similar analysis in the context of 
cannabis dependence treatment. They found that as many as 80% of 
community-dwelling individuals with cannabis dependence in the NESARC data 
were excluded by Humphreys-identified criteria13 from cannabis treatment RCTs.  
Velasquez et al.23 found that 52.9% (N=317) of the 599 individuals who 
were screened for eligibility for a multisite RCT of alcoholism treatment (Project 
Match) were excluded from the RCT. Similarly, Sofuoglu et al.24 found that 70.8% 
(N=608) out of the 859 individuals who were screened by telephone for eligibility 
to participate in the inpatient cocaine treatment study were excluded from the 
study. Frewen et al.25 used the data of patients from publically funded drug and 
alcohol center in Sydney, Australia, and found that of the 169 patients that were 
screened for eligibility, 52.1% (N=88) did not meet eligibility criteria and were 
excluded from RCT for cannabis treatment. A recent review11 of these studies on 
impacts of eligibility criteria on the RCT sample representativeness estimated 
that between 64 and 96% of potential study participants can be excluded from 
SUD treatment RCTs with commonly used eligibility criteria.  
Not only exclusion from the study but also refusal to participate in RCTs 
impacts the sample representativeness of the RCTs. Melberg and Humphreys26 
reviewed 98 illicit drug use treatment RCTs and found that an average of 29% of 
potential RCT participants were ineligible and an additional 29% of the eligible 
 7 
participants refused to participate. An average of 36% of potential RCT 
participants were ineligible and an additional 32% of the eligible participants 
refused to participate when each study was weighted by sample size. The 
authors suggested that this indicates that RCTs with a larger number of 
participants do not necessarily include more representative samples. 
While past studies assessed the hypothetical impact of eligibility criteria on 
the RCT sample representative, very few studies with some recent exceptions 
assessed the sample representativeness of the RCTs as compared with the 
intended target populations. A study by Susukida et al.12 compared the 
characteristics of participants in ten RCTs from the National Institute of Drug 
Abuse Clinical Trials Network and the intended target populations and found 
substantial differences in sociodemographic characteristics. The proportion of 
individuals with more than 12 years of education and those who had full-time jobs 
were significantly higher among the RCT samples than among target 
populations. Another recent study by Blanco et al.27 also directly compared the 
RCT sample of the web-based intervention with the target population of 
individuals with SUD drawn from the Wave 1 of the NESARC. They found that 
there were substantial differences between the RCT sample and the target 
population in terms of race, educational attainment, marital status, and types of 
primary substance use problems.  
 
Limited generalizability of SUD RCTs 
Very few studies have examined the impact of sample representativeness on 
RCT findings. Humphreys et al.14 assessed how applications of commonly used 
eligibility criteria impacted the outcomes of patients by using the data of real-
world SUD treatment-seeking patients whose outcomes were known. They 
compared the outcomes between the samples with and without the application of 
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five widely used treatment research eligibility criteria, which are psychiatric 
problems, medical problems, social-residential instability, low 
motivation/noncompliance, and drug problems. It was shown that while eligibility 
criteria of psychiatric and medical problems created only a moderate bias (10% 
or less change) in outcome estimates, eligibility criteria of social-residential 
instability, low motivation/noncompliance, and drug use created a larger (up to a 
51% change) bias in outcome estimates. More recently, Blanco et al.27 applied a 
weighting-based method similar to the one used in this dissertation to the sample 
of a web-based SUD RCT and reweighted the outcomes of the RCT to the target 
population drawn from the NESARC data. They found that reweighting the RCT 
sample with the target population weight made the significant treatment effect of 
the web-based SUD RCT statistically insignificant.  
 
Generalizing the findings of RCTs to target populations 
Stuart and colleagues28 proposed a statistical method to assess the sample 
representativeness of RCT samples using propensity score techniques. This 
method is to compute conditional probability, p, (similar to a propensity score) for 
being included into the RCT sample based on a number of covariates which are 
commonly observable in both the RCT sample and the target population. The 
difference in average propensity scores (Δp) between the RCT sample and its 
target population indicates how similar or different the distributions of 
characteristics between RCT sample and the target population are. Larger values 
of p indicate that the RCT sample and the target population tend to differ from 
each other, while smaller values of Δp indicate that the RCT sample and the 
target population tend to share more similarities. Stuart and colleagues28 applied 
this method to a school-based RCT intervention, and they  estimated a 
standardized p of 0.73. This suggests “substantial difference” between the two 
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samples. In observational studies, it is generally considered that values of p 
larger than 0.25 indicate substantial difference between two samples.29–31 
Mamdani et al.32 suggested more conservative cutoff of p  larger than 0.10 as 
indicating a meaningful difference between two samples.  
The estimated propensity score can be used to generalize the findings from 
RCTs to intended target populations. Cole and Stuart33 applied this method to 
generalize the results from a AIDS Clinical Trial Group (ACTG) study using data 
from a representative target population of a HIV-infected individuals in the US. 
The authors computed the inverse probability of selection weight, 1 − � �⁄ , 
where � was the estimated conditional propensity score based on characteristics 
of study participants in the ACTG trial and the target population. The authors 
found that men, White patients, Hispanic patients and patients older than 30 
years old had higher probability of being included in the RCT sample and these 
characteristics also moderated the treatment effect in the ACTG trial. This 
dissertation applies this propensity-score based method in the context of the 
SUD RCTs to assess the sample representativeness and the generalizability of 
the findings from multiple SUD RCTs.  
 
1.3. Overview of specific aims 
The study has the following specific aims and hypotheses:  
Aim 1: To assess generalizability of the outcomes from ten SUD RCTs to target 
populations in usual treatment settings. 
Chapter 2 covered Aim 1 and compared RCT sample treatment effects and 
the population effects of SUD treatment. The population effects were estimated 
through statistical weighting, which re-computes the effects in RCTs such that 
the participants in the RCTs had similar characteristics to individuals in the target 
populations. Chapter 2 used multi-site ten RCTs (five trials of 
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Buprenorphine/Naloxone detoxification for opioid dependence, three trials of 
motivational enhancement/interviewing on SUD, and two trials of motivational 
incentives for cocaine, methamphetamine or amphetamine use) drawn from 
National Institute of Drug Abuse (NIDA) Clinical Trials Network (CTN) and the 
target population of individuals seeking treatment in usual SUD treatment 
settings drawn from the Treatment Episodes Data Set-Admissions (TEDS-A). A 
total of 3,592 patients in ten RCTs and 1,602,226 patients from usual SUD 
treatment settings between 2001 and 2009 were included in the analyses of 
Chapter 2. Generalizability of treatment effects on three types of outcomes were 
examined: retention, urine toxicology, and abstinence. The RCT sample 
treatment effects were weighted to resemble target populations with propensity 
scores representing the conditional probability of participating in RCTs.  
 
 Aim 2: To assess generalizability of the outcomes from a web-based SUD 
intervention (Therapeutic Education System) to target populations in usual 
treatment settings as well as in community-dwelling settings.  
Chapter 3 covered Aim 2 and assessed the generalizability of the findings 
from a multi-site web-based SUD intervention. We compared the sample of a 
web-based SUD intervention (Therapeutic Education System vs. Treatment-as-
usual) (n=507) with two types of target populations: SUD treatment-seeking 
individuals drawn from the Treatment Episodes Data Set-Admissions (TEDS-A) 
and community-dwelling individuals with recent substance use, whether or not 
they sought treatment, drawn from the National Survey on Drug Use and Health 
(NSDUH). With propensity scores of RCT participation, we weighted the 
treatment effects on retention and abstinence to make the trial sample resemble 




Aim 3: To compare the effectiveness of four different pharmacological treatments 
for cocaine use disorders while taking into account generalizability of the 
treatment effects estimated through RCTs to two types of target populations in 
usual treatment settings as well as in community-dwelling settings.  
Chapter 4 covered Aim 3 and conducted a meta-analysis to synthesize the 
treatment effectiveness of multiple medications for cocaine dependence and to 
assess comparative treatment effectiveness while incorporating the 
generalizability of the RCT findings to the target populations. We drew Individual-
level data from four RCTs (Reserpine, Modafinil, Buspirone, and Ondansetron 
vs. placebo) from the National Institute of Drug Abuse Clinical Trials Network 
(n=456). The treatment effects on retention and abstinence from each RCT were 
weighted to make the distribution of the characteristics of the RCT sample similar 
to those of target population of treatment-seeking patients (Treatment Episodes 
Data Set-Admissions; TEDS-A) as well as target population of individuals with 
cocaine dependence in the general population (National Survey on Drug Use and 
Health; NSDUH). We used a one-step meta-analytic approach to synthesize the 
generalized outcomes from four RCTs using individual-level data. We also 
conducted a network meta-analysis to assess comparative effectiveness across 
these four treatments with study-level data while accounting for the 
generalizability of the RCT findings.  
 
1.4. Public health significance 
The findings from this dissertation will provide insight into differences 
between participants of SUD treatment RCTs and target patient populations in 
various settings based on direct comparisons of these groups. The results of this 
dissertation will also provide a better understanding of whether and how the 
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differences in the characteristics between the RCT samples and the target 
populations can influence the findings of the RCTs. Particularly, for interventions 
with potential scalability to large target populations like web-based SUD 
interventions,34 the findings of this dissertation will have implications for careful 
consideration of the representativeness of the RCT sample with regard to target 
population of potential users of these types of intervention. The findings from this 
dissertation will also have implications for other trial networks, such as the 
National Cancer Institute (NCI) Clinical Trial Network Program, which intends to 
disseminate treatments on a large scale.35 As attention to large-scale 
dissemination and implementation of evidence-based treatments and 
interventions increases,36 it becomes increasingly important to understand the 
applicability of the findings of RCTs in different populations with varying 
characteristics, contexts, and locations. As the movement towards “practical 
clinical trials” to assess treatment effect in real-world settings increases, a 
growing number of RCTs with less stringent eligibility have been conducted37. 
However, relaxing eligibility criteria may not be always feasible especially when 
there are safety concerns for patients such as allergic reactions to certain 
medications. In these cases, the weighting-based method that this dissertation 
employs might provide useful solutions to examine to what extent the findings of 
RCTs are applicable to target populations.  
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CHAPTER 2 Generalizability of Findings from Randomized Controlled Trials: 
Application to the National Institute of Drug Abuse Clinical Trials Network 
  
2.1. Abstract 
Aims: To compare randomized trial (RCT) sample treatment effects and the 
population effects of substance use disorder (SUD) treatment. 
Design: Statistical weighting was used to re-compute the effects from ten RCTs 
such that the participants in the trials had characteristics that resembled those of 
patients in the target populations. 
Settings: Multi-site RCTs and usual SUD treatment settings in the United States. 
Participants: A total of 3,592 patients in ten RCTs and 1,602,226 patients from 
usual SUD treatment settings between 2001 and 2009.   
Measurements: Three outcomes of SUD treatment were examined: retention, 
urine toxicology, and abstinence. We weighted the RCT sample treatment effects 
using propensity scores representing the conditional probability of participating in 
RCTs.  
Findings: Weighting the samples changed the significance of estimated sample 
treatment effects. Most commonly, positive effects of trials became statistically 
non-significant after weighting (three trials for retention and urine toxicology, and 
one trial for abstinence); but also, non-significant effects became significantly 
positive (one trial for abstinence), and significantly negative effects became non-
significant (two trials for abstinence). There was suggestive evidence of 
treatment effect heterogeneity in subgroups that are under- or over-represented 
in the trials, some of which were consistent with the differences in average 
treatment effects between weighted and unweighted results.  
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Conclusions: The findings of RCTs do not appear to be directly generalizable to 
target populations when the RCT samples do not adequately reflect the target 
populations and there is treatment effect heterogeneity across patient subgroups.  
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2.2. Introduction 
There is growing concern that the results from randomized controlled trials 
(RCTs) may not generalize to real world settings.2–6,38 Perhaps due to this, many 
interventions with strong efficacy evidence either cannot be replicated or produce 
smaller effects in different settings.7,8 Limitations in generalizability of the findings 
from RCTs pose major clinical and policy concerns because RCTs are 
considered the most accepted study design for choosing evidence-based 
practices. The randomized study design does not necessarily ensure external 
validity, which means that the findings of an RCT may not be applicable to all 
individuals for whom treatment or intervention is intended. Individuals who 
volunteer to participate in RCTs are typically different from those who refuse to 
participate. Furthermore, strict eligibility criteria are likely to make the findings 
less applicable to subgroups who are excluded from trials.  
Particularly in the context of RCTs of treatments for substance use 
disorders (SUD), there is a growing body of research indicating that the samples 
recruited to the RCTs are substantially different from target populations.1,2,39,40 It 
is also known that women, especially pregnant women, African-Americans, low-
income individuals, and individuals with more severe alcohol, drug, and 
psychiatric problems are disproportionately under-represented in SUD treatment 
RCTs.9,40 Furthermore, commonly used eligibility criteria in SUD treatment RCTs 
exclude substantial portions of the target population. However, the prevalence of 
such exclusions varies across studies.  For example, Humphreys et al.9 found 
that 20% to 33% of patients with alcohol use disorders would be excluded by the 
eligibility criteria commonly used in RCTs of alcohol use disorders, whereas, 
Okuda et al.2 found that as many as 80% of patients with cannabis dependence 
would be excluded by the commonly used eligibility criteria for cannabis 
treatment RCTs. A recent review study by Moberg and Humphreys11 estimated 
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that commonly used exclusion criteria in SUD trials would exclude between 64% 
and 95% of potential participants.  
A study by Susukida et al.12 compared the characteristics of participants in 
ten RCTs from the National Institute of Drug Abuse Clinical Trials Network and 
the intended target populations and found substantial differences in 
sociodemographic characteristics. The proportion of individuals with more than 
12 years of education and those who had full-time jobs were significantly higher 
among the RCT samples than among target populations.  
While improving the representativeness of RCTs participants may be a 
reasonable solution to this problem, logistical considerations including concerns 
about safety, non-adherence with treatment, and drop-out from the study often 
limit investigators’ ability to expand eligibility criteria. There is some evidence that 
the exclusion criteria of SUD treatment trials have become increasingly more 
restrictive over the years.13 Government-funded SUD treatment trials are 
particularly likely to use such restrictive exclusion criteria.13 Assessing how well 
the study samples represent potential target populations with regard to various 
sociodemographic and clinical characteristics, and how deviations from 
representativeness may have impacted the results of the study are important for 
evaluating the real-world relevance of RCTs.14 While previous studies have 
examined how well RCT samples represent target populations,2,9,12,40 few studies 
have assessed how representativeness of the RCT sample may affect the 
findings of the RCTs when generalized to a target population.28 Furthermore, 
there is little understanding of how heterogeneity of treatment effects among 
various subgroups that are differentially represented in RCTs may explain the 
generalizability of results. Generalizability of the findings for the RCTs is 
compromised when there are treatment effect modifiers that differ between the 
RCT samples and the target populations. If treatment effects among under- or 
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over-represented subgroups in RCTs are heterogeneous, the findings from the 
RCT may not directly carry over to a population of interest.41 
The main aims of this study were (1) to estimate sample treatment effects 
and the population effects of RCTs of SUD treatment, and (2) to examine the 
treatment effect heterogeneity by subgroups that are under- or over-represented 
in the trials. To weight the results to a target population, we applied a weighting-
based approach, which weights the RCT samples to resemble the target 
populations,28,33 and is similar to inverse probability weighting for non-
experimental studies.42 This method was used by Stuart et al.41 to examine the 
generalizability of the results of a randomized behavioral intervention trial in 
schools. This current study extends the analysis by Susukida et al.12, which 
compared differences in characteristics of individuals who participated in ten 
SUD RCTs with individuals from target populations for whom these treatments 
are intended. We hypothesized that the estimated effects would be different in 
the RCT samples and the target populations of interest, which would be partially 
explained by differences in treatment effect by subgroups of individuals recruited 




The RCTs used in this study were the same RCTs used in our prior 
analyses.12 Briefly, a total of 3,592 individuals from ten RCTs from the National 
Institute of Drug Abuse (NIDA) Clinical Trials Network (CTN) and 1,602,226 
individuals from the Treatment Episodes Data Set-Admissions (TEDS-A) 
between 2001 and 2009 were included. The NIDA CTN studies are multisite 
RCTs conducted in various settings in the United States to assess the 
effectiveness of treatments for SUD.43 For each RCT sample, we drew a 
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separate corresponding target sample from TEDS-A. The TEDS-A includes data 
on approximately 1.5 million patients (≥ 12 years old) admitted every year to SUD 
treatment facilities nationally. Every state that receives public funding for SUD 
treatment programs is mandated to provide records of all patients to the TEDS-A. 
Although the TEDS-A is one of the largest data sets that covers patients with 
SUD in the US, some states limit the data to individuals whose treatment is 
covered by the state substance use agency funds (such as Federal Block Grant 
funds).44 Treatment facilities that are managed by private agencies and hospitals 
are usually excluded from the TEDS-A unless they are licensed by the state 
substance abuse treatment agency.  
The main criteria for defining target populations were the SUD that each 
RCT targeted, inclusion age criteria of RCT, treatment settings (outpatient vs. 
inpatient), and the years when the RCT was conducted. For example, the target 
population for CTN0001, an RCT of Buprenorphine/Naloxone Detoxification for 
individuals aged 18 years or older seeking treatment for opioid dependence in 
inpatient treatment settings, enrolled into the study between February 2001 and 
August 2002, was drawn from the population of patients in TEDS-A between 
2001-2002 who were 18 years or older who received treatment for opioid 
dependence in inpatient treatment settings. For an RCT that targeted a more 
specific population such as pregnant women, we used the additional criteria to 
identify the target population. At the time of this study, target populations could 
be identified for a total of ten CTN studies included in the NIDA CTN database. 
eTable 1 (online supplement) in Susukida et al.12 describes the definitions of the 
target populations for each RCT. 
Table 2.1. describes characteristics of each CTN trial. Five trials 
(CTN000145, CTN000245, CTN000346, CTN001047, CTN003048) examined the 
effectiveness of Buprenorphine/Naloxone detoxification (Bup/Nx-Detox) for opioid 
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dependence. Three trials (CTN000449, CTN000550, CTN001351) examined the 
effectiveness of motivational enhancement/interviewing (MEI) on SUD, and two 
trials (CTN000652, CTN000753) examined the effectiveness of motivational 
incentives (Incentives) for cocaine, methamphetamine or amphetamine use.  
 
Measures 
There were nine comparable variables between the CTN and TEDS-A 
datasets: sex, race-ethnicity, age, educational attainment, employment status, 
marital status, admission through criminal justice, intravenous drug use, and the 
number of prior treatments for SUD. These nine variables were used to model 
the probabilities of trial participation, which were then used as weights to 
generalize the outcomes from the RCTs.    
The following three outcomes from RCTs were generalized to the target 
populations: successful retention in the study, submission of a substance-free 
urine sample, and days of abstinence in the past 30 days. Remaining in the study 
until the end of the trial was considered successful retention in the study. 
Similarly, submitting a substance-free urine sample at the end of the trial was 
considered an indicator of successful detoxification. Study participants reported 
the number of days of use of the target substances in the past 30 days. Number 
of days abstinent was defined by the self-reported number of days free from the 
target substance in the past 30 days.    
 
Statistical Analysis 
This study used a weighting-based approach to estimate the treatment 
effects in the target populations. This approach is similar to inverse probability 
weighting for non-experimental studies, where researchers estimate the causal 
effect by making the exposed and unexposed samples in an observational study 
 20 
similar with respect to observed characteristics.42 In this study, we weighed both 
arms of the RCT samples to resemble the target populations.28,33 Unweighted 
and weighted analyses were conducted for all three outcomes. Thus, while the 
unweighted analyses estimate the effects in the trial samples, the weighted 
analyses estimate the population effects. The models used for the analyses were 
logistic regression for the binary outcomes of retention and urine toxicology, and 
linear regression models for days of abstinence in the past 30 days. Assuming 
that randomization was successful in each trial, we did not adjust for baseline 
variables within the trial samples.   
To account for missing data, we performed multiple imputation with the 
STATA ice command (version 13) to generate 50 imputed data sets. eTable 2 in 
Susukida et al.12 described the detailed patterns of missing data in each CTN 
sample and the corresponding target population, and the detailed procedures of 
multiple imputation. 
Trial participation weights for each trial were calculated as 1 − � �⁄ , 
where � was the mean propensity score across the 50 imputed data sets, defined 
as the probability of a patient participating in the RCT conditional on the nine 
variables described above. A non-parametric random forest, using the 
“randomForest”54 package in R,55 was used to calculate the propensity scores for 
each patient.56,57 Weighted analyses with the weights for each trial, 1 − � �⁄ ,  
were conducted by using the STATA pweights command (version 13). In addition 
to comparing the statistical significance of the treatment effects from unweighted 
and weighted models, we statistically compared the treatment effect sizes of 
unweighted and weighted models, using the STATA suest (seemingly unrelated 
estimation) command.58 
We conducted subgroup analyses to examine the treatment effect 
heterogeneity by subgroups of RCT participants to help explain the differences 
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between weighted and unweighted models. For example, if the statistical 
significance of the treatment effect of the RCT were different before and after 
weighting, and our analyses indicated that the RCT had enrolled a significantly 
larger proportion of patients with higher education, we examined heterogeneity of 
treatment effects between the low and high education subgroups in the RCT. We 
stratified RCT samples by subgroups based on variables used to model the 
probability of trial participation and performed chi-squared tests for binary 
outcomes and t-tests for continuous outcomes to explore treatment effects in 
different subgroups. We conducted subgroup analyses for the CTN studies that 
produced statistically significant results when weighted, but not when unweighted 
or vice versa. Furthermore, we only focused on the characteristics that 
significantly differed between RCT samples and the corresponding target 
populations. Our rationale for these further analyses was to identify the 
contribution of treatment effect heterogeneity to the biases in outcome produced 
as a result of the differences in the characteristics of the RCT samples and the 
target populations.  
 
2.4. Results 
Comparison of unweighted outcomes and outcomes weighted by propensity 
scores 
Table 2.2. presents the results of the analyses for the effect of treatment on 
trial retention. Odds ratios (ORs) from both unweighted and weighted logistic 
regression models for all 10 trials are presented with the 95% confidence 
intervals. The unweighted models estimated the effects in the RCT samples 
while the weighted models estimated the effects that would be expected if the 
RCT sample had the same characteristics as the target populations. In 
unweighted analyses, treatment was associated with significantly greater odds of 
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retention in 5 trials (CTN0001, CTN0002, CTN0003, CTN0006, and CTN0010). A 
significantly positive effect on retention in CTN0006, CTN0003, and in CTN0010 
became statistically non-significant after weighting. Furthermore, there was a 
significant difference in estimated effects between unweighted and weighted 
models for CTN0002.   
Table 2.3. presents comparisons of unweighted and weighted results of the 
studies for urine toxicology. Odds ratios (ORs) from both unweighted and 
weighted logistic regression models for all 10 trials are presented. In unweighted 
analyses, treatment was associated with significantly greater odds of drug-free 
urine samples in 5 trials (CTN0001, CTN0002, CTN0003, CTN0006, and 
CTN0010). Significantly positive effects on urine toxicology in CTN0006, 
CTN0003, and in CTN0010 became statistically non-significant after weighting. In 
all 10 trials, however, there was no statistically significant difference between 
unweighted and weighted models with regard to the estimated effects from the 
unweighted and weighted models.   
Table 2.4. presents comparisons of unweighted and weighted linear 
regression results for the effect of treatment on days of abstinence in the past 30 
days. Results from both unweighted and weighted linear regression models for 
all 10 trials are presented. In unweighted analyses, treatment was associated 
with significantly higher number of days of abstinence in one trial (CTN0001) and 
a significantly smaller number in 2 trials (CTN0004 and CTN0030). The 
significant positive effect in CTN0001 became non-significant after weighting. 
Similarly, the significant negative effects in CTN0004 and CTN0030 became 
statistically non-significant after weighting. Furthermore, the statistically non-
significant positive effect in CTN0002 became statistically significant after 
weighting and, a statistically non-significant negative effect in CTN0010 became 
significant after weighting. There was a significant difference between 
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unweighted and weighted effect estimates for CTN0002 but not for any of the 
other trials.  
 
Subgroup analysis for treatment effect heterogeneity 
As the results of our prior analyses12 indicated, the composition of the CTN 
samples deviated significantly from the composition of the target populations with 
regard to the socio-demographic characteristics on which these samples were 
compared. Appendix Table 2.1. presents the results of comparisons of the 
characteristics of RCT samples and target populations. To simplify the 
interpretation of the results, we presented the comparison using dichotomized 
variables in this study.  
The proportion of those with 12 years or higher education was significantly 
larger among patients who participated in RCTs than among the target 
populations in seven of the ten trials (CTN0001, CTN0002, CTN0003, CTN0004, 
CTN0005, CTN0010, and CTN0030). The proportion of those with full-time jobs 
was also significantly larger among patients who participated in RCTs than 
among patients in target populations in all nine trials in which information on 
employment status was collected (CTN0001, CTN0002, CTN0003, CTN0004, 
CTN0005, CTN0006, CTN0007, CTN0013, and CTN0030). Furthermore, each 
RCT and its target population differed in terms of other characteristics although 
the patterns varied across trials. There were statistically significant differences in 
the proportions of female patients, certain race-ethnicity groups, age groups, 
married patients, patients who were admitted through the criminal justice system, 
patients with IV drug use, and patients with more than 5 prior treatments, 
between individual RCTs and the corresponding target populations.  
We conducted subgroup analyses for outcomes of RCTs that showed a 
difference between the sample treatment effects and the population treatment 
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effects subsequent to weighting. To limit the number of tests, these analyses 
were restricted to subgroups that met criteria for a statistically significantly 
difference in composition between the RCT samples and the corresponding 
target populations. Thus, we conducted 76 subgroup analyses (see Appendix 
Table 2.2.).  
Results of subgroup analysis of treatment effects are presented in 
Appendix Table 2.3. There were some consistent patterns in the directions of 
change in outcomes from weighting and examination of treatment effect 
heterogeneity by subgroups. As an example, in the case of CTN0006, some 
subgroups that were overrepresented in the RCT samples (e.g, females, married 
patients, those with full time jobs, and those not using IV drugs) also showed 
evidence of larger treatment effects on retention as compared with 
underrepresented subgroups. As another example, in the case of CTN0003, 
some subgroups that were overrepresented in the RCT samples (e.g, White 
patients, those with ≥12 years of education, those with full time jobs, and patients 
not admitted through criminal justice) also showed evidence of larger treatment 
effects on retention as compared with underrepresented subgroups. Weighting 
this RCT sample to be more similar in composition to the target sample 
increased the weights for subsamples with smaller effect sizes, leading to 
statistically non-significant estimates of the population effects.  
 
2.5. Discussion 
This study demonstrated that the observed outcomes of some RCTs may 
not carry over directly to potential target populations. In most cases, statistically 
significant results seen in the RCT samples became non-significant when 
weighted to the target population. These differences in effect estimates between 
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the RCT samples and the target populations could be partially explained by the 
patterns in treatment effect heterogeneity across subgroups.  
A recent study by Stuart et al.41 that applied the same weighting-based 
method to generalize the results of a behavioral intervention trial in school 
settings found that the weighted effect of intervention was just slightly attenuated 
compared to the effect seen in the trial. To our knowledge, the present study is 
the first to use this weighting approach to estimate target population effects using 
the results of SUD RCTs. Previous studies showing substantial differences 
between SUD RCT samples and target populations implied that the difference 
might affect generalizability of the results from RCTs;2,9,12,40 however, those 
studies did not attempt to estimate the population effects from trial results.  
Our study findings have implications for the external validity of results from 
SUD RCTs. Susukida et al.12 showed substantial variability in the likelihood of 
being in RCT samples across patient subgroups and indicated that poor 
representation of target populations might impact the generalizability of findings 
from RCTs. The results of the present study confirm this prediction by revealing 
differences in the statistical significance between the sample treatment effects 
and the population treatment effects. The present study also found suggestive 
evidence that treatment effect heterogeneity among under- or over-represented 
subgroups of patients in the RCTs could partially explain why the population 
treatment effects estimated by weighting the RCT samples differed from the 
sample effects.  
The results of this study should be interpreted in light of several limitations. 
First, the number of characteristics measured in both the RCT samples and the 
target populations was limited. Therefore, it is likely that weights calculated in this 
study could not take into account other characteristics that may differ between 
the RCT samples and target populations and moderate treatment effects. 
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Second, due to the significant differences between the RCT samples and their 
target populations, the weighting-based method may not have adequately made 
the RCT samples resemble the target populations to estimate the population 
treatment effects. In Susukida et al.,12 for all ten RCT studies, the difference in 
mean propensity scores between the RCT sample and its target population was 
much larger than the cut-off proposed by Stuart.29 Weighting the RCT samples to 
estimate the population treatment effects is more reliable when the RCT samples 
and the target populations are more similar to start with. Third, difference 
between the sample treatment effect and the population effect could be due to 
difficulties in equating the trial sample and population with respect to the 
covariates. For example, for the urine toxicology outcome in CTN0010, where a 
significant effect became non-significant after weighting, the distributions of 
educational attainment as well as marital status were significantly different 
between the RCT sample and its target population even after weighting. 
Furthermore, we did not find consistent patterns of the treatment effect 
heterogeneity of study participants by educational attainment and marital status. 
Fourth, the primary goal of the ten CTN studies was not to assess treatment 
effect heterogeneity. Hence, the subgroup analyses conducted for this study 
were not adequately powered and the findings only provide suggestive evidence 
of treatment effect heterogeneity across subgroups of patients. Fifth, TEDS-A 
data do not include some groups of patients. Therefore, the population treatment 
effects estimated by this study may not represent treatment effects among all 
recipients of SUD treatment in the US. Furthermore, patients in TEDS-A 
represent treatment-seeking individuals and do not necessarily represent the 
whole population of individuals who need treatment and are potential recipients 
of such treatments. Results may differ if future studies use broader definition of 
target populations, including non-treatment-seeking individuals. Finally, our 
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estimates of the RCT results do not necessarily correspond to the published 
reports by primary investigators. The primary investigators of the CTN RCTs 
operationalized outcomes differently.45–53 For example, some original outcome 
studies published by primary investigators reported treatment effects by trial 
sites;50 whereas, the site identifiers were not provided in the publically available 
NIDA data. Therefore, we were not able to replicate these site-specific results. In 
order to compare how weighting affects the findings across the studies, we chose 
to use the same measures across the studies based on the raw RCT data 
provided in the NIDA CTN repository. It should also be noted that the unweighted 
sample treatment effects were not always significantly positive. This may have 
been possibly due to receipt of standard care among patients in the control arm. 
Acknowledging these limitations, results from this study provide a first 
insight into whether and how deviations in RCT sample representativeness from 
target populations influence the observed outcomes of SUD RCTs. It is critical for 
future CTN studies to place greater emphasis on external validity of RCTs, 
particularly because a primary goal of the NIDA CTN was to provide data on 
SUD treatments that can be disseminated in usual care settings. As interest in 
comparative effectiveness research in real-world treatment settings increases, 
RCTs for mental health treatments increasingly use less stringent eligibility 
criteria for participation, which may improve generalizability of the findings of 
RCTs 37. However, relaxing eligibility criteria may not be feasible for all RCTs, 
especially when there are safety concerns for patients such as allergic reactions 
to certain medications. In such cases, the weighting-based method that this study 
employed might be useful to examine to what extent the findings of RCTs are 
applicable to target populations. As attention to large-scale dissemination and 
implementation of evidence-based treatments and interventions increases,36 it 
becomes increasingly important to understand the applicability of the findings of 
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RCTs in different populations with varying characteristics, contexts, and 
locations. It is also important to consider the change in the nature of target 
populations especially in the context of the United States, where more people are 
eligible for health insurance as a part of Affordable Care Act legislation,59 which 
may affect profiles of patient groups who seek and access treatments.    
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Table 2.1. Description of CTN studies  
CTN Study 
Number 
Study Title Years Sample 
Size 
Arm  
(T vs. C) 
Example of Eligibility Criteria 
Buprenorphine/naloxone (Bup/Nx) detoxification 
CTN0001 Buprenorphine/Naloxone (Bup/Nx) versus 





Inpatient treatment-seeking males and 
non-pregnant and non-lactating females, 
15 years and older, with DSM-IV opiate 
dependence 
CTN0002 Buprenorphine/Naloxone (Bup/Nx) versus 





Outpatient treatment-seeking males and 
non-pregnant and non-lactating females, 
15 years and older, with DSM-IV opiate 
dependence 




516 7-day vs. 28-
day Bup/Nx 
Taper 
Outpatient treatment-seeking males and 
non-pregnant and non-lactating females, 
15 years and older, with DSM-IV opiate 
dependence 
CTN00010 Buprenorphine/Naloxone (Bup/Nx) Facilitated 




154 Bup/Nx vs. 
Detox 
Outpatient treatment-seeking males and 
non-pregnant and non-lactating females, 
14-21 years old, with DSM-IV-TR opiate 
dependence 
CTN00030 Buprenorphine/Naloxone Treatment Plus 




653 Bup/Nx + 
Counseling vs. 
Bup/Nx 
Outpatient treatment-seeking males and 
non-pregnant and non-lactating females, 
18 years and older, with DSM-IV opiate 
dependence 
Motivational enhancement/interviewing (MEI) 
CTN0004 Motivational Enhancement Treatment (MET) To 
Improve Treatment Engagement and Outcome in 




461 MET vs. 
Counseling as 
usual (CAU) 
Outpatient treatment-seeking individuals 
for any substance use disorder with use of 
any substance in the past 28 days, 18 
years and older 
CTN0005 Motivational Interviewing (MI) To Improve 
Treatment Engagement and Outcome in 




423 MI vs. 
treatment-as-
usual (TAU) 
Outpatient treatment-seeking individuals 
for any substance use disorder with use of 
any substance in the past 28 days, 18 
years and older 
CTN0013 Motivational Enhancement Therapy (MET) to 
Improve Treatment Utilization and Outcome in 
Pregnant Substance Users 
2003-
2006 
200 MET vs. TAU Pregnant women (Less than 32 weeks), 
identified as needing substance abuse 
treatment, 18 years and older 
Motivational incentives (Incentives) 
CTN0006 Motivational Incentives for Enhanced Drug 
Abuse Recovery: Drug Free Clinics 
2001-
2003 
454 Incentives vs. 
TAU 
Outpatient treatment-seeking individuals 
with evidence of cocaine or 
methamphetamine use, without gambling 
problems 
CTN0007 Motivational Incentives for Enhanced Drug 
Abuse Recovery: Methadone Clinics 
2001-
2003 
388 Incentives vs. 
TAU 
Outpatient treatment-seeking individuals 
with evidence of cocaine or 
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Table 2.2. Comparison of unweighted (RCT sample effect) and weighted 
(population effect) odds ratios of treatment effect on retention    
 
Retention 
 OR 95%CI  p Comparison of the effect estimates from 
the unweighted and weighted models 
CTN1      
Unweighted 13.34 5.11 34.83 <.01  
F(1, 225)=0.14, p=.71 Weighted 9.10 1.54 53.99 .02 
CTN2      
Unweighted 3.49 1.91 6.38 <.01  
Weighted 17.78 6.38   49.58 <.01 F(1, 459)=7.19,  p=.01 
CTN3      
Unweighted 2.06 1.39 3.05 <.01  
Weighted 1.16 0.42 3.25 .77 F(1, 1031)=1.04, p=.31 
CTN4      
Unweighted 1.24 0.85 1.81 .26  
Weighted 1.26 0.50 3.21 .63 F(1, 921)=0.00, p=.98 
CTN5      
Unweighted 1.26 0.80 1.98 .31  
Weighted 1.08  0.47 2.47 .85 F(1, 845)=0.10, p=.75 
CTN6      
Unweighted 1.63 1.11  2.39 .01  
Weighted 1.26 0.62 2.53 .52 F(1, 907)=0.41, p=.52 
CTN7      
Unweighted 1.21 0.81     1.80 .36  
Weighted 0.55 0.17   1.80 .32 F(1, 771)=1.51, p=.22 
CTN10      
Unweighted 2.68 1.32    5.44 <.01  
Weighted 1.46 0.08 26.07 .80 F(1, 307)=0.16, p=.69 
CTN13      
Unweighted 0.54 0.28 1.05 .07  
Weighted 0.31 0.08 1.19 .09 F(1, 399)=.52, p=.47 
CTN30      
Unweighted 0.91 0.67  1.24 .55  
Weighted 0.95 0.30 2.99 .93    F(1, 1305)=.00, p=.95 
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Table 2.3. Comparison of unweighted (RCT sample effect) and weighted 
(population effect) odds ratios of treatment effect on urine toxicology 
Urine toxicology 
 OR 95%CI  p Comparison of the  effect estimates from 
the unweighted and weighted models 
CTN1      
Unweighted 8.22 3.26     20.72 <.01  
Weighted 8.26 1.43 47.76  .02 F(1, 225)=0.00, p=.99 
CTN2      
Unweighted 10.80 2.52  46.21 <.01  
Weighted 59.76 10.89 327.87 <.01 F(1, 459)=2.24, p=.13 
CTN3      
Unweighted 1.84 1.28 2.64 <.01  
Weighted 1.36 0.54 3.43 .52    F(1, 1031)=0.36, p=.55 
CTN4      
Unweighted 1.11 0.77 1.60 .59    
Weighted   1.32 0.54 3.26 .54 F(1, 921)=0.13, p=.72 
CTN5      
Unweighted 1.18 0.80      1.72 .40  
Weighted 1.79 0.80 3.99 .15 F(1, 845)=0.87, p=.35 
CTN6      
Unweighted 1.48 0.99 2.20 .05  
Weighted 1.13 0.56 2.28 .74 F(1, 907)=0.44, p=.51 
CTN7      
Unweighted 0.87 0.51  1.49 .62  
Weighted 0.48 0.13 1.82 .28 F(1, 771)=0.65, p=.42 
CTN10      
Unweighted 5.55 2.71 11.36 <.01  
Weighted 4.71  0.29 76.54 .28 F(1, 307)=0.01, p=.91 
CTN13      
Unweighted 0.72 0.41      1.25 .24  
Weighted 1.38 0.36 5.21 .64 F(1, 399)=0.78, p=.38 
CTN30      
Unweighted 0.72 0.41      1.25 .24  
Weighted 1.38 0.36 5.21 .64 F(1, 1305)=0.00, p=.97 
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Table 2.4. Comparison of unweighted (RCT sample effect) and weighted 
(population effect) regression coefficients of treatment effect on self-reported 
days of abstinence in the past 30 day 
  
Abstinence 
 OR 95%CI  p Comparison of the  effect estimates from the 
unweighted and weighted models 
CTN1      
Unweighted 6.47 1.60  11.35 .01  
Weighted 0.58 -3.82 4.98 .79 F(1, 225)=2.67, p=.10 
CTN2      
Unweighted 3.07 -1.77   7.90 .21  
Weighted 13.10 5.82 20.37 <.01 F(1, 459)=4.95, p=.03 
CTN3      
Unweighted 0.63 -1.75 3.00 .61  
Weighted 3.92 -1.31 9.15 .14  F(1, 1031)=1.28, p=.26 
CTN4      
Unweighted -2.52 -4.26    -0.79 <.01  
Weighted -3.02 -6.98 0.94 .14 F(1, 921)=0.05, p=.82 
CTN5      
Unweighted -0.84 -2.88  1.20 .42    
Weighted 1.31 -5.57 8.20 .71 F(1, 845)=0.35, p=.55 
CTN6      
Unweighted 0.16 -1.36     1.68 .83  
Weighted 2.53 -0.34 5.41 .08 F(1, 907)=2.07, p=.15 
CTN7      
Unweighted 0.26 -1.34   1.87 .75  
Weighted -0.12 -1.89 1.66 .90  F(1, 788)=0.10, p=.75 
CTN10      
Unweighted -0.94 -5.44  3.57 .68  
Weighted -3.38 -5.57 -1.19 <.01 F(1, 307)=0.96, p=.33 
CTN13      
Unweighted 0.72 -2.35     3.78 .64  
Weighted 1.70 -4.06 7.46 .56 F(1, 399)=0.09, p=.77 
CTN30      
Unweighted -1.79 -3.37  -0.20 .03  
Weighted 0.85 -4.08 5.78 .74 F(1, 1305)=1.00, p=.32 
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CHAPTER 3 Generalizability of the Findings from a Randomized Controlled Trial 
of a Web-based Substance Use Disorder Intervention 
 
3.1. Abstract  
Background: There is a growing concern for generalizability of the findings from 
randomized controlled trials (RCT) of interventions for substance use disorders 
(SUD). 
Objectives: This study assessed the generalizability of the findings from a multi-
site web-based SUD intervention.  
Methods: The sample of a web-based SUD intervention (Therapeutic Education 
System vs. Treatment-as-usual) (n=507) was compared with the characteristics 
of the two types of target populations: SUD treatment-seeking individuals from 
the Treatment Episodes Data Set-Admissions (TEDS-A) and community-dwelling 
individuals with recent substance use, whether or not they sought treatment, from 
the National Survey on Drug Use and Health (NSDUH). Using propensity scores 
of RCT participation, we weighted the treatment effects on retention and 
abstinence to make the trial sample resemble these target populations.  
Results: Substantial differences between the RCT sample and the target 
populations were reflected in significant differences in the mean propensity 
scores (1.62 and 1.14 standard deviations for the TEDS-A and NSDUH, 
respectively, at P < 0.001). The population effect on abstinence (12 weeks and 6 
months) was insignificant after weighting the data by TEDS-A and NSDUH 
generalizability weights. There was no significant difference between the 
population effect and unweighted effect on retention. Suggestive evidence of 
treatment effect heterogeneity was found across subgroups, some of which were 
consistent with the differences between weighted and unweighted treatment 
effects.  
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Conclusions: Generalizability of the findings of the RCT appears to be limited 
when the RCT sample does not well-represent the target populations and there is 




Substance use disorders (SUD) impose significant societal and economic 
burdens. Tobacco use is the leading cause and alcohol use the third leading 
cause of preventable deaths in the United States.60 Overdose death rates of illicit 
drugs as well as prescription drugs are steadily increasing over time. As of 2015, 
52,404 individuals died of drug overdose, which is almost double the number of 
overdose deaths in 2004.61 Annual costs of lost work productivity, crime and 
health care associated with abuse of tobacco, alcohol and illicit drugs is 
estimated to be more than $700 billion in the United States, which is more than 
4.1% of the annual GDP.62–64   
In spite of high prevalence of SUD and its various negative health 
consequences,65 many individuals with SUD do not receive treatment.66–68 Using 
the Wave 2 data of the National Epidemiologic Survey on Alcohol and Related 
Conditions, Blanco et al.68 found that only 13% of those with drug dependence 
and 5% of those with alcohol dependence sought treatment within the first year 
of the disorder onset. Although there are a number of effective evidence-based 
interventions for SUD,69 strong stigma toward these conditions70 and the limited 
access to SUD specialty treatment71 often prevent those with SUDs from 
receiving effective treatment. There is a clear need for SUD treatments with 
greater acceptability and accessibility.  
Web-based SUD treatment is a promising behavioral intervention to treat 
individuals with SUDs who may not be willing or able to receive traditional face-
to-face interventions.34 A web-based SUD treatment can offer various potential 
benefits including lower implementation cost, greater scalability, greater 
accessibility in remote or rural areas with limited options for SUD specialty 
treatment, higher confidentiality, 24-hour accessibility, opportunities for more 
frequent and longer intervention duration, and greater convenience and flexibility 
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of access from patients’ homes without a need for appointments.34,72 A growing 
number of randomized controlled trials (RCTs) demonstrated that web-based 
SUD interventions had higher treatment retention and resulted in increased level 
motivation to change, decreased substance use, and greater knowledge about 
SUD as compared with treatment-as-usual.34  
The promising treatment effects shown by the RCTs of web-based SUD 
interventions, however, do not necessarily guarantee the external validity of the 
findings to different populations. Particularly, limited external validity of the 
findings from RCTs is a concern when the characteristics of RCT participants are 
different from those of the target population for whom an intervention is intended. 
There are a growing number of studies suggesting that the participants of RCTs 
may not represent the target populations well, especially in the context of SUD 
treatments. A recent review by Moberg and Humphreys11 showed that commonly 
used exclusion criteria in RCTs of SUD treatments would exclude between 64% 
and 95% of potential participants. In addition to exclusion criteria, refusal to 
participate in the RCTs is another critical factor that may impact the 
representativeness of the RCT samples. In the context of RCTs of SUD 
treatments, refusal to participate in the RCTs is especially concerning because 
many individuals with SUD do not receive treatment voluntarily and are referred 
to treatment through the criminal justice system. A study by Susukida et al.12 
directly compared characteristics between actual participants in ten SUD RCTs 
and the target populations of individuals receiving SUD treatment in usual care 
settings and found that a significantly higher proportion of the RCT participants 
had higher educational attainment and full-time jobs than those in target 
populations.  
Another study by Susukida et al.73 examined how lack of 
representativeness of the SUD RCT samples affected the findings of the RCTs. 
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Susukida et al.73 used statistical weighting techniques to make the SUD RCT 
samples resemble the target populations and showed that significant sample 
treatment effects often became insignificant after weighting. This same study 
also demonstrated suggestive evidence of treatment effect heterogeneity across 
under- or over-represented subgroups of the RCT participants, some of which 
could potentially explain why weighted and unweighted treatment effects were 
different.  
Web-based SUD interventions potentially have greater scalability to 
broader target populations than clinic-based interventions. However, very few 
previous studies assessed the representativeness of the participants of RCTs of 
web-based SUD interventions as compared with the intended target populations 
and whether and how the sample representativeness impacts the generalizability 
of RCT findings. A recent study by Blanco et al.27 directly compared the RCT 
sample of the web-based intervention, the Therapeutic Education System (TES), 
with two types of target populations: SUD treatment seeking population and 
those with SUD regardless of their treatment seeking behavior, both drawn from 
the Wave 1 of the National Epidemiologic Survey on Alcohol and Related 
Conditions (NESARC), which was conducted between 2001 and 2002. They 
found substantial differences in characteristics between the RCT sample and the 
two target populations and also demonstrated that the significant treatment effect 
of TES became insignificant after the sample was statistically weighted to 
resemble these target populations. However, illicit drug use in the US has been 
increasing in the past 10 to 15 years and the NESARC target populations used in 
Blanco et al.27 may not appropriately represent the current population with SUD. 
According to the report by the National Institute of Drug Abuse (NIDA),74 
approximately 9.4 percent of the US population used an illicit drug during the 
past month in 2013 while the rate was 8.3 percent in 2002.74 Given these 
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changes in nationwide trends in substance use behaviors in recent years, it is 
important assess the representativeness of the SUD RCT trials compared with 
the target populations drawn from more recent years in the US. Furthermore, in 
Blanco et al.,27 both the treatment seeking target population and the general 
target population were drawn from the NESARC, which was a general household 
population survey and did not capture marginalized population groups such as 
homeless and/or incarcerated individuals.  
The aims of this study were (1) to assess the sample representativeness of 
a large multi-site web-based SUD intervention RCT with two target populations: 
individuals with recent drug use who are admitted into SUD treatment in usual 
care settings, and individuals with recent drug use in the general population 
regardless of treatment seeking status, and (2) to estimate sample treatment 
effects and the population effects of the web-based intervention. Generalizing 
treatment effects to these two diverse target samples addresses two distinct 
policy questions: 1) the efficacy of the treatment for individuals who seek 
treatment in usual care settings and 2) the efficacy of treatment if treatment is 
disseminated to the much wider population group who are not currently seeking 
any treatment, but could potentially benefit from it. Unlike a recent study by 
Blanco et al.,27 this study drew target populations from data of more recent years. 
Moreover, while one of the target populations in Blanco et al.27 consisted of a 
group of individuals self-selected into SUD treatment, the target population of 
those receiving SUD treatment in this study was not entirely self-selected into 
treatment because it included patients referred to treatment through legal 
authorities such as criminal justice.  
We first conducted a pairwise comparison of characteristics of the 
participants of the web-based SUD RCT and the two target populations. Next, we 
summarized differences between the RCT and the target populations by 
 40 
computing propensity scores which represent the probabilities of participating in 
the RCT based on the eight commonly observed characteristics between the 
web-based SUD RCT and two target populations. We then used the estimated 
propensity scores to weight the RCT sample to resemble the target 
populations,28,33 which is a similar approach to inverse probability weighting for 
non-experimental studies.42 Finally, subgroup analyses were conducted to 
examine the treatment effect heterogeneity by under- or over-represented 
subgroups of RCT participants to help explain the differences between weighted 
and unweighted models. The findings have implications for assessing the 
representativeness of the samples and generalizability of the results of web-




Data for the “Web-delivery of Evidence-Based, Psychosocial Treatment for 
Substance Use Disorders” were drawn from the National Institute of Drug Abuse 
Clinical Trials Network (NIDA) Clinical Trials Network (CTN) Data share 
Website.43 This trial sought to examine the effectiveness of an intervention called 
Therapeutic Education System (TES) plus motivational incentives for treatment 
of substance disorders.75 The TES is a computerized psychosocial intervention, 
which includes skill building modules and incentives that are provided upon 
completion of the modules and abstinence from substance use.76 The trial 
recruited study participants between June 2010 and August 2011 and 
randomized individuals seeking outpatient treatment for SUD into two arms. One 
arm received treatment as usual (TAU), comprised of standard SUD outpatient 
treatment and the other arm TAU plus TES. The trial lasted 12 weeks and 
enrolled adults in outpatient SUD treatment who reported any illicit drug use in 
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the past 30 days. A total of 507 patients were included in this study. Illicit drugs 
included cocaine, opiates (morphine, codeine, and heroin), amphetamines, 
cannabinoids (THC), methamphetamines, benzodiazepines, oxycodone, 
methadone, barbiturates, and MDMA.  
The RCT sample was compared to two target populations. The first target 
population was drawn from the 2012 Treatment Episodes Data Set-Admissions 
(TEDS-A)–the most recent data available at the time of this writing. The TEDS-A 
is an administrative database maintained by the Center for Behavioral Health 
Statistics and Quality (CBHSQ) of the Substance Abuse and Mental Health 
Services Administration (SAMHSA). The TEDS-A includes annual data on more 
than 1.5 million admissions of individuals aged 12 years old or older to substance 
abuse treatment facilities across the US that are publically funded. We limited the 
TEDS-A sample to patients who were 18 years or older, received treatment in 
outpatient settings, and reported illicit drug use in the past 30 days to make the 
sample comparable to the RCT sample. Since only a small portion of the TEDS-
A was missing (n = 14,712, 2.4% out of 610,766), we conducted statistical 
analysis with complete cases (n = 596,054).  
The second target population was drawn from the 2013 and 2014 National 
Survey on Drug Use and Health (NSDUH) –the most recent NSDUH data 
available at the time of this writing. The NSDUH is an annual cross-sectional 
national survey administered by the CBHSQ, SAMHSA. The NSDUH interviews 
household residents aged 12 years old or older randomly drawn from the fifty US 
states and Washington D.C. and collects information about their patterns of 
substance use and mental health problems. We limited the sample to those who 
were 18 years or older, and reported illicit drug use in the past 30 days. There 
were no missing data in the NSDUH and a total of 5,717 NSDUH participants 
were included in this study. Since some demographic were oversampled in the 
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NSDUH surveys (e.g., young adults), the sampling weight was taken into account 
in all the statistical analyses in this study.   
 
Measures 
There were eight common variables assessed in the RCT sample and the target 
populations: sex, race-ethnicity (white, black, Hispanic and other), age (recoded 
into 18-34, 35-49, 50 or older), educational attainment (less than high school, 
high school, more than high school), employment status (full-time, part-time, out 
of labor, unemployed), marital status (Never married, married, 
separated/divorced/widowed), intravenous drug use, and the history of past 
treatments for SUD.  
Two outcomes from the RCT were generalized to the target populations: 
successful retention in the study and abstinence from substance use. Successful 
retention in the study was defined by remaining in the RCT at each assessment 
point, which occurred at the end of trial (12 weeks), 3-month follow-up, and 6-
month follow-up. Study participants were considered “abstinent” if they submitted 
negative urine toxicology sample and they reported no drug use or heavy alcohol 
drinking in the last 4 days of each assessment point.  
 
Statistical analysis 
We first compared the RCT sample with the two target populations with regard to 
the eight observed characteristics noted above. Pearson’s 2 tests were 
conducted to compare the composition of the RCT sample and the target 
populations.  
Next, we estimated propensity scores, which is the conditional probability of 
participating in the RCT based on the eight variables, for every individual both for 
the RCT sample and the target populations. The propensity score was estimated 
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using the non-parametric random forests method56,57 as implemented in the R 
package ‘randomForest’.54 The random forests method has been shown to have 
a higher predictive accuracy than parametric methods.77 Another advantage of 
the random forests method is that it reduces misclassification errors through 
bootstrap resampling.78 The bootstrap resampling method draws the same 
number of observations from the larger group to match the number of the 
observations from the smaller group in the data. In the case of this study, for 
example, the number of observations of the RCT sample was substantially 
smaller than that of the TEDS-A target population and the NSDUH sample. 
Especially when estimating propensity score in such “class-imbalanced data”, 
this down-sampling method performs well to decrease misclassification error.79  
After estimating the propensity score for each individual, we calculated a 
difference of mean propensity scores between the RCT sample as a group and 
the target populations. This mean propensity score difference, p, was 
introduced by Stuart et al.80 as a measure to evaluate the representativeness of 
the RCT sample as compared with the target population. Standardized p, which 
is p divided by the pooled standard deviation of the propensity scores, is a 
summary index representing the difference between the RCT sample and its 
target population. In observational studies, it is generally considered that values 
of p larger than 0.25 indicate substantial difference between two samples.29–31 
Mamdani et al.32 suggested more conservative cutoff of p  larger than 0.10 as 
indicating a meaningful difference between two samples.  
We calculated weight for trial participation as 1 − � �⁄  for each individual, 
with which weighted regression analyses were conducted with the STATA 
pweights command (version 13). We not only compared the statistical 
significance of the treatment effects from unweighted and weighted models, but 
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also statistically compared the effect sizes of unweighted and weighted models, 
with the STATA suest (seemingly unrelated estimation) command.58 
Lastly, subgroup analyses were conducted to examine the treatment effect 
heterogeneity by subgroups of RCT participants to explore potential reasons why 
the treatment effects from weighted and unweighted models might differ. For 
instance, if the significant unweighted treatment effect of the RCT became 
insignificant after weighting, and the RCT had a significantly larger proportion of 
married participants, we may observe stronger treatment effect among married 
individuals than non-married individuals. We conducted stratified analyses of 
treatment effects by subgroups based on variables used to estimate propensity 




Comparison of characteristics of RCT sample and target populations 
Table 3.1. presents the characteristics of the RCT participants and the two 
target populations. As compared with the TEDS-A target population, the RCT 
sample had significantly lower proportions of Hispanic individuals, those with 
intravenous drug use, and those with a history of prior SUD treatment. On the 
other hand, the RCT sample had significantly higher proportions of those with 12 
years or longer educational attainment and those with full time jobs, as compared 
with the TEDS-A target population.  
As compared to the NSDUH target population, the RCT sample had 
significantly lower proportions of those between age 18-34, those with 12 years 
or longer educational attainment, individuals with fulltime jobs, married 
individuals, and those with a history of prior SUD treatment. In contrast, the RCT 
sample had significantly higher proportions of Black individuals, those between 
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ages 35 and 49, and those with intravenous drug use as compared with the 
NSDUH target population.   
 
Comparison of propensity scores of RCT sample and target populations 
Table 3.2. presents the comparison of the mean propensity scores for 
participating in the RCT obtained from comparison of the RCT and the target 
population characteristics. The estimated mean propensity score for the RCT 
sample was significantly larger than for the target populations. The standardized 
p for both target populations was substantially larger than the 0.25 standardized 
p cut-off suggested in the literature.29–31  
Figure 3.1. shows the density plots of propensity scores for the RCT sample 
and the target populations. The more limited overlap the two density plots have, 
the less similar the RCT sample and the target population are. The RCT sample 
had a smaller overlapping area with the TEDS-A target population, which is 
consistent with the larger p between the RCT sample and the TEDS-A target 
population. The RCT sample shared a larger overlapping area of density plots 
with the NSDUH target population, which is consistent with the smaller p 
between the RCT sample and the NSDUH target population.  
 
Comparison of unweighted outcomes and outcomes weighted by propensity 
scores 
Table 3.3. presents the unweighted and weighted treatment effects on trial 
retention and abstinence. We presented odds ratios (ORs) from both unweighted 
and weighted logistic regression analyses with the 95% confidence intervals. The 
unweighted treatment effects represent the effects in the RCT sample while the 
weighted treatment effects represent the effects that would be expected if the 
RCT sample was made to resemble the target populations. In unweighted 
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analyses, treatment was associated with significantly greater odds of abstinence 
at 12 weeks and 6-month follow-up. Significant treatment effects on abstinence 
at 12 weeks and 6-month follow-up became statistically non-significant after 
weighting with both TEDS-A and NSDUH generalizability weights. Treatment 
effect on retention was insignificant both in the unweighted and weighted 
analyses. However, for both abstinence and retention outcomes, comparison of 
treatment effect sizes did not reveal significant differences between unweighted 
and weighted models with either TEDS-A or NSDUH generalizability weights.  
 
Subgroup analysis for treatment effect heterogeneity 
We presented results of subgroup analyses of treatment effects in 
Appendix Table 3.1. There were some consistent patterns of treatment effect 
heterogeneity by subgroups of RCT participants with the differences in outcomes 
between unweighted and weighted models. For example, for abstinence at 12 
weeks, some subgroups that were overrepresented in the RCT sample (e.g, non-
married individuals, those without IV drug use, and those without history of prior 
SUD treatment) as compared with the TEDS-A target population also showed 
evidence of larger treatment effects on abstinence as compared with 
underrepresented subgroups. As compared with the NSDUH target population, 
some subgroups that were overrepresented in the RCT sample (e.g, Black 
patients, those with less than 12 years of educational attainment, non-married 
individuals, and those without history of prior SUD treatment) also showed 
evidence of larger treatment effects on retention as compared with 
underrepresented subgroups. Weighting this RCT sample to resemble the 
distribution for the target populations decreased the weights for over-represented 
subsamples with larger effect sizes, which may potentially explain insignificant 




This study demonstrated significant differences between the RCT sample of 
a web-based SUD intervention, the Therapeutic Education System (TES), and 
target populations of potential recipients of the intervention. Whether the target 
population consisted of treatment-seeking individuals with recent drug use 
(TEDS-A) or individuals with recent drug use regardless of treatment seeking 
status (NSDUH), the composition of the RCT sample substantially differed from 
those of the target populations.  
Furthermore, the summary index of these differences, p, far exceeded the 
standardized p cutoff 0.2529–31 or 0.1032 for both target populations (1.62 and 
1.14 standard deviations for the TEDS-A and NSDUH, respectively), indicating 
substantial differences between the RCT sample and the target populations. 
Standardized p can be interpreted similarly to Cohen’s d effect size.81 Cohen’s 
d values of 1.62 and 1.14 are equivalent to a 42% and 57% probability that the 
distributions of the RCT sample and the target population will overlap, 
respectively. The density plots of estimated propensity scores confirmed this by 
showing a relatively narrow overlapping area between the RCT sample and each 
target population.  
This study also demonstrated that the observed promising findings of the 
TES intervention may not be directly applicable to potential target populations. 
We showed that significant treatment effects on abstinence at 12 weeks and 6-
month follow-up became insignificant after weighting. We showed some 
suggestive evidence that these differences between the unweighted sample 
treatment effects and the estimated population effects could be partially 
explained by the treatment effect heterogeneity across under- and over-
represented subgroups of RCT participants.  
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The findings of this study are consistent with the previous studies by 
Susukida et al.,12 which found statistically significant differences between the 
samples from ten SUD RCTs and the corresponding target populations. The 
findings of this study are also consistent with Susukida et al.,73 which found the 
significance of estimated sample treatment effects was different from that of the 
population effects when the distribution of characteristics of RCT samples were 
made to resemble the distribution of the target populations by using the same 
statistical weighting techniques that this study used. Especially in the context of 
the generalizability of the findings of a web-based SUD intervention, this study’s 
findings echo the findings of the recent study by Blanco et al.,27 which found the 
significant treatment effect of TES estimated through RCT became insignificant 
after weighting the sample to resemble the target populations drawn from 2000-
2001 NESARC data. Our study confirms that their findings hold when the 
generalizability of the TES RCT was assessed with the target populations from 
recent years. Furthermore, unlike treatment-seeking population drawn from 
general population in by Blanco et al.,27 the TEDS-A target population in this 
study was not entirely self-selected into treatment, which included some 
marginalized population such as those admitted treatment through criminal 
justice system.  
Several limitations should be taken into consideration when interpreting this 
study’s findings. First, only a limited number of characteristics were assessed in 
the RCT sample and the target populations. Therefore, the estimated propensity 
scores did not reflect other characteristics that may have differed between the 
RCT and the target populations. Second, the RCT sample that this study used 
came from the sample collected in the clinical (outpatient) settings. Since web-
based intervention could be implemented in non-clinical settings such as school 
or community settings, the applicability of the findings of this study might be 
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limited to the context of the web-based SUD RCTs in clinical settings. Third, 
although the TEDS-A is one of the largest administrative data sources that cover 
the data on most patients with SUD in the US, some states exclude patients 
whose treatment is not covered by the state substance use agency funds such 
as Federal Block Grant funds.44 Patients who received treatment at private 
hospitals are usually excluded from the TEDS-A unless they have licenses from 
the state substance abuse treatment agency. Therefore, the TEDS-A might have 
not necessarily represented the entire population of patients with SUD in the US. 
Fourth, the original TES RCT did not intend to examine treatment effect 
heterogeneity. Therefore, the subgroup analyses we conducted were not 
sufficiently powered and we could only show suggestive evidence of treatment 
effect heterogeneity across subgroups of the trial participants.   
In the context of these limitations, findings from this study provide insight 
into differences between the RCT participants of the web-based SUD 
intervention and two types of target populations from recent years. The results of 
this study also indicate how poor sample representativeness of the RCT 
compared with target populations impacted the observed findings of the web-
based SUD intervention. Given the great potential for scalability of web-based 
SUD interventions,34 the representativeness of the sample with regard to target 




Table 3.1. Comparison of baseline characteristics (%) of the samples in the Therapeutic 













 Percent Percent Percent 
Sex 
  Female  










Race    
White  58.2 59.0 66.4 
Black  21.9 22.3 14.8 
Hispanic  10.8 14.1 12.9 
Other  9.1 4.7 5.9 
Age    
18-34  51.1 58.3 54.0 
35-49  34.3 29.4 23.4 
50 and over 14.6 12.3 22.6 
Education    
<12 years 23.3 32.2 14.0 
12 years 76.7 67.8 86.0 
Employment    
Full-time 40.0 16.4 53.2 
Part-time 23.1 9.8 17.5 
Out of labor 10.7 31.2 21.1 
Unemployed 26.2 42.7 8.1 
Marital Status    
Married 14.2 15.0 27.0 
Never married 60.8 64.7 55.2 
Separated/divorced/widowed  25.0 20.3 17.9 
IV drug use    
Yes  7.5 19.0 1.0 
No 92.5 81.0 99.0 
Prior treatments    
Yes 7.7 58.3 18.8 
No 92.3 41.7 81.2 
Notes: Pearson’s χ2 test was conducted. Numbers shown in bold type indicate statistically significant 






Table 3.2. Comparison of propensity scores between the Therapeutic Education System RCT and target samples from the 
Treatment Episodes Data-Admission (TEDS-A) and the National Survey of Drug Use and Health (NSDUH). 
Target population = TEDS-A 
CTN0044 TEDS-A pa Pooled standard deviation  Standard pb t-Test P-value 
0.77 0.26 0.51 0.31 1.62 36.35 <0.001 
Target population = NSDUH 
CTN0044 NSDUH pa Pooled standard deviation  Standard pb t-Test P-value 
0.69 0.34 0.36 0.32 1.14 25.22 <0.001 
a Δp is difference between propensity scores of the RCT sample and the target population.  
b Standardized Δp is computed as Δp divided by pooled standard deviation.
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Table 3.3. Comparison of unweighted (RCT sample effect) and weighted (population effect) odds ratios of 




1. Weight is calculated as (1-p)/p, where p is a propensity score of being in a trial sample. 
2. Weight was truncated at 95 percentiles to eliminate extreme weights.   
3. **p<0.01, *p<0.05. 
4. Individuals were considered “abstinent” if they submitted negative urine toxicology sample and they reported no drug use or heavy alcohol 




 Unweighted Weighted (with TEDS-A) Weighted (with NSDUH) 
 OR 95%CI  p OR 95%CI  p Comparison  
(unweighted vs. weighted)  
OR 95%CI  p Comparison  
(unweighted vs. weighted) 
Retention 12 weeks 0.92 0.55, 1.52 0.74 0.80 0.30, 2.18 0.67 2 =0.05, p= 0.82 1.79 0.63, 5.12 0.28 2 =1.26, p= 0.26 
Retention 3 months 0.60 0.33, 1.08 0.09 1.09 0.35, 3.35 0.88 2 =0.85, p= 0.36 0.68 0.19, 2.42 0.55 2 =0.03, p= 0.87 
Retention 6 months 1.02 0.72, 1.45 0.90 1.16 0.60, 2.25 0.66 2 =0.11, p= 0.74 0.76 0.35, 1.64 0.48 2 =0.48, p= 0.49 
Abstinence 12 weeks 1.67** 1.15, 2.44 <0.01 1.62 0.80, 3.26 0.18 2 =0.01, p= 0.94 2.01 0.87, 4.65 0.10 2 =0.15, p= 0.70 
Abstinence 3 months 1.18 0.82, 1.71 0.37 0.74 0.37, 1.48 0.39 2 =1.38, p= 0.24 1.64 0.73, 3.69 0.23 2 =0.53, p= 0.47 





Figure 2.1. Density plots of propensity scores in CTN0044 and target samples 
from the Treatment Episodes Data-Admission (TEDS-A) and the National Survey 






CHAPTER 4 Comparing pharmacological treatments for cocaine dependence: 
Addressing generalizability in meta-analysis 
 
4.1. Abstract  
Background: There are few head-to-head comparisons of cocaine dependence 
medications, and combining data from different studies is fraught with 
methodological challenges. Furthermore, randomized controlled trials (RCTs) 
often incorporate selective samples of patients, thus limiting generalizability of 
findings. We addressed these limitations by applying a novel meta-analytic 
approach to data on the efficacy of medications for cocaine dependence.    
Methods: Individual-level data from four RCTs (Reserpine, Modafinil, Buspirone, 
and Ondansetron vs. placebo) were obtained from the National Institute of Drug 
Abuse Clinical Trials Network (n=456). The treatment effects on retention and 
abstinence from these trials were weighted to make the trial sample resemble 
treatment-seeking patients (Treatment Episodes Data Set-Admissions; TEDS-A) 
and individuals with cocaine dependence in the general population (National 
Survey on Drug Use and Health; NSDUH). We synthesized the generalized 
outcomes using a one-step meta-analytic approach with individual-level data and 
network meta-analysis with study-level data.  
Results: After weighting the data by TEDS-A and NSDUH generalizability 
weights, the overall population effect on retention was significantly larger than the 
unweighted effect. However, there was no significant difference between the 
population effect and unweighted effect on abstinence. Weighting also changed 
the ranking of the effectiveness across treatments. For retention, the second 
most efficacious treatment, Ondansetron, became the most efficacious after 
applying NSDUH generalizability weights. For abstinence, the least efficacious 
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treatment, Reserpine, became the second most efficacious after weighting for 
both target populations.  
Conclusions: Application of generalizability weights to meta-analysis is feasible 
and provides a useful tool for assessing comparative effectiveness of treatments 
for substance use disorders, with potential utility for comparative assessments in 
other fields as well.    
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4.2. Introduction 
In 2014, the United States had approximately 913,000 individuals (0.29% of 
the US population) who met the Diagnostic and Statistical Manual of Mental 
Disorders criteria for cocaine dependence or abuse during the past 12 months.82 
According to the 2011 Drug Abuse Warning Network (DAWN) report,83 nearly 
40% of drug misuse or abuse-related emergency room visits (505,224 out of 1.3 
million visits) involved cocaine. Chronic cocaine use is associated with a number 
of adverse outcomes including psychotic symptoms,84 cardiovascular 
complications,85 intracerebral hemorrhage,86 and movement disorders such as 
Parkinson’s disease.87 It is also known that those with regular lifetime use of 
cocaine have significantly higher likelihood of premature deaths as compared 
with non-cocaine using peers.88  
There is clearly a need for evidence-based interventions for cocaine use 
disorders. A number of behavioral interventions have been shown to be effective 
for treating cocaine use disorders including contingency management,89 
cognitive-behavioral therapy,90 and therapeutic communities.91 However, there 
are no pharmacological treatments for cocaine use disorder currently approved 
by the U.S. Food and Drug Administration.92  A number of potential medications 
for cocaine use disorders have been examined in randomized clinical trials 
(RCTs).89,90,93–95 Existing studies targeted several neurobiological agents with 
putative effects on receptors considered to be involved in cocaine use disorder, 
such as dopamine, serotonin, gamma-aminobutyric acid (GABA), glutamate, and 
norepinephrine.96 The list of medications tried in past studies is long and includes 
the glutaminergic medication modafinil,97 GABAergic medications such as 
baclofen, tiagabine, and topiramate,94 disulfiram,98 antidepressants such as 
desipramine99 and cocaine vaccination that produces antibodies against 
cocaine.100   
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Despite some promising evidence of effectiveness in individual RCTs, meta-
analyses of medications for cocaine use disorders have failed to produce 
evidence of overall treatment effectiveness of these medications or to identify 
clear advantages for one pharmacological agent.93,95 These previous meta-
analyses of medications for cocaine use disorders used a traditional approach of 
synthesizing study-level data typically obtained from publications. This approach 
makes it difficult to take into account the differences in the composition of RCT 
samples and to reliably compare different treatments.  
Advances in meta-analytic methodology now make it possible to synthesize 
individual-level data from different RCTs.101 Furthermore, the newly introduced 
method of network meta-analysis, also referred to as mixed treatment meta-
analysis or multiple treatment comparison meta-analysis, now makes it possible 
to estimate comparative effectiveness across multiple interventions that are not 
evaluated against each other in any one study.102  
Another major limitation of past RCTs for treatment of cocaine use disorder 
is the selective nature of the RCT samples24 which limits the external validity, or 
generalizability of the findings of the RCTs to the target population. This concern 
is not limited to cocaine treatment RCTs as there is a growing concern that the 
findings from RCTs in a number of health fields may not be generalizable to real 
world settings.2–6,38 However, the concerns may be amplified with regard to RCTs 
for treatments of substance use disorders (SUD) because of the stigma 
associated with such treatment and the specialized setting where treatments are 
offered.   
There is a growing body of research showing that individuals participating in 
RCTs are substantially different from the target populations.1,2,39,40 According to a 
recent review by Moberg and Humphreys11 which synthesized 15 studies 
examining the impact of SUD trial exclusion criteria on distributions of 
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participants’ characteristics, commonly used exclusion criteria in SUD trials 
would exclude between 64% and 95% of potential participants. A study by 
Susukida et al.12 found substantial differences in distributions of characteristics 
between RCT samples and the target populations by comparing the 
characteristics of participants in ten RCTs from the National Institute of Drug 
Abuse Clinical Trials Network (NIDA-CTN) and the intended target populations 
consisting of people who seek treatment for SUD in usual care settings. A more 
recent study by Susukida et al.73 found that the significance of estimated sample 
treatment effects was different from that of the population effects when the 
distribution of characteristics of RCT samples were made to resemble the 
distribution of the target populations by using statistical weighting techniques. 
Most commonly, positive effects of trials in unweighted RCTs became statistically 
non-significant after weighting. To the best of our knowledge, however, no past 
studies of SUD treatments have synthesized data from individual RCTs with a 
view to the generalizability of results for the target population or have attempted 
to improve generalizability using statistical adjustments.  
In this study, we embarked on a meta-analysis of individual-level data from 
four RCTs of medication used for treatment of cocaine dependence. We used the 
techniques of network meta-analysis to compare the effects of these four 
treatments while considering generalizability of the findings of the RCTs to the 
target populations and adjusting the results to make them more generalizable. 
The original RCTs had each compared the efficacy of one medication with 
placebo. Two target populations were selected to investigate and enhance 
generalizability of the findings from meta-analyses: individuals seeking treatment 
for cocaine dependence at usual care settings and individuals with cocaine 
dependence in the general population, regardless of their treatment seeking 
behavior. Generalizing to these two diverse target samples addresses two 
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distinct policy questions: 1) the efficacy of the treatment for individuals who seek 
treatment in usual care settings and 2) the efficacy of treatment if treatment is 
disseminated to the much wider population group who are not currently seeking 




RCT data were drawn from the NIDA-CTN Data share Website.43 The 
NIDA CTN studies are nationwide multi-site clinical trial studies to assess the 
effectiveness of SUD treatments. At the time of this writing, four data sets of 
RCTs of cocaine dependence medications were available (CTO0001, MDS0004, 
CTN00052 and CTO0005). CTO0001 (n=119) examined the effectiveness of 
Reserpine, a dopamine depletory medication,51 MDS0004 (n=210) examined the 
effectiveness of Modafinil, a non-amphetamine psychostimulant,103 CTN00052 
(n=62) examined the effectiveness of Buspirone, an anxiolytic drug,104 and 
CTO0005 (n=65) examined the effectiveness of Ondansetron, a medicine mainly 
used for prevention of nausea.105 All four RCTs included a placebo arm and 
involved adults who met the Diagnostic and Statistical Manual of Mental 
Disorders-Fourth Edition (DSM-IV) 106 for cocaine dependence. A total of 456 
patients from four RCTs were included in this study.  
We selected two different target populations for generalizability weighting 
of the RCT samples. The first target population was drawn from the TEDS-A in 
2012 (the most recent wave of TEDS-A data available at the time of this writing). 
The TEDS-A is a part of the Behavioral Health Services Information System 
(BHSIS), which is maintained by the Center for Behavioral Health Statistics and 
Quality (CBHSQ), Substance Abuse and Mental Health Services Administration 
(SAMHSA). More than 1.5 million admissions aged 12 years old or older are 
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included in the TEDS-A every year. We limited the TEDS-A sample to patients 
with DSM-IV cocaine dependence who were 18 years old or older (n=36,997) for 
generalizability to the treatment-seeking population.  
The second target population was drawn from the NSDUH 2013 and 2014 
(the most recent waves of the survey available at the time of this writing). The 
NSDUH is an annual cross-sectional national survey also administered by the 
CBHSQ, SAMHSA. Every year NSDUH interviews a nationally representative 
sample of household residents 12 years old or older about their patterns of 
substance use and mental health problems. We limited the sample to those who 
met DSM-IV cocaine dependence criteria in the past year (n=235) for 
generalizability to the cocaine dependent individuals in the general population. 
The sampling weight was taken into account in every statistical analysis in this 
study because some demographic groups were oversampled in the NSDUH 
surveys (e.g., young adults).  
 
Measures 
We identified eight comparable variables between the RCTs and the target 
populations with which to compute statistical weights for generalizing RCT 
outcomes to the two target populations: sex, race-ethnicity, age, educational 
attainment, employment status, marital status, intravenous drug use, and the 
number of past treatments for SUD.  
We generalized the following two outcomes from the RCTs to the target 
populations: successful retention in the study, and days of abstinence in the past 
30 days. Successful retention in the study was defined as participation in the 
study until the end of the trial. Days of abstinence were calculated as the 
numbers of days without self-reported cocaine use in the past 30 days.  
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We used the same outcomes across the four RCTs to allow us to compare 
how statistical weighting impacts the outcomes across the studies. The original 
investigators of the four RCTs reported on different outcomes. For example, 
while the original investigators of CTN00052104 (the Buspirone trial) used 
maximum days of continuous cocaine abstinence as the primary outcome, the 
investigators of CTO0005105 (the Ondansetron trial) used percentage of study 
participants with a cocaine-free week as their primary outcome. Therefore, the 
observed estimates of RCT results in this study were not necessarily the same 
as the findings in published reports by original investigators.103–105,107 
 
Statistical analysis 
Analyses were conducted in four stages. First, we compared the eight 
characteristics noted above between the RCT samples and the target 
populations. Pearson’s chi-squared tests were conducted to examine if there 
were significant differences in the distributions of the eight variables between the 
RCT samples and the target populations.  
As the TEDS-A includes a significant amount of missing data (12.7 %), 
similar to our previous generalizability studies using the TEDS-A target 
population data,12,73 we used multiple imputation with the STATA ice command 
(version 13) and created 50 imputed data sets. A detailed description of the 
missing data is presented in Appendix Table 4.1. 
Second, to generalize the results from the RCTs to the target populations, 
we used a weighting-based method, which weights RCT samples to resemble 
the target populations.28,33 This approach is similar to the inverse probability 
weighting method, which is often used for non-experimental studies.42 Stuart et 
al.41 used this approach to assess the generalizability of the findings of an RCT 
of behavioral intervention trial in school settings. To assess generalizability of the 
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findings of each RCT, we computed trial participation weights for each trial as 1 − � �⁄ , where � was the propensity score, defined as the conditional 
probability of an individual participating in the RCTs based on the eight variables 
described above. The mean propensity score across 50 imputed data sets was 
used for TEDS-A to take into account the missing data. There were no missing 
data in the NSDUH sample. To calculate the propensity scores, we used a non-
parametric random forests approach, using the “randomForest”54 package in R.55 
Although the random forests approach has some advantages over a parametric 
approach such as a higher predictive accuracy and the ability to reduce extreme 
propensity scores,77 we still encountered some outlying values for propensity 
scores and trial participation weights. In order to improve the performance of the 
propensity score based weighting, we used weight trimming, also referred as 
truncation, in which we replaced extreme large values at the 95th percentile 
values following the method introduced in a study by Lee et al.108 We conducted 
weighted regression analyses with the weights for each trial, 1 − � �⁄ ,  using the 
STATA pweights command (version 13). 
Third, we conducted unweighted and weighted meta-analyses of four RCTs 
to estimate the overall treatment effect of cocaine dependence medications. 
Unweighted and weighted analyses were conducted for two outcomes: retention 
and abstinence. The unweighted analyses estimated the sample treatment 
effects while the weighted analyses estimated population-generalized effects. For 
the binary outcome of retention, we used logistic regression models; whereas, for 
the continuous measure of days of abstinence in the past 30 days, we used 
linear regression models. Baseline variables in the trial samples were not 
adjusted, assuming that randomization was successful in each trial. We 
estimated multi-level mixed effects models, which allow random intercepts and 
coefficient on treatment assignment variable. The standard errors were clustered 
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at trial level. In addition to comparing the statistical significance of the treatment 
effects from unweighted and weighted regression models, we also statistically 
compared the treatment effect sizes of unweighted and weighted models, using 
the STATA suest (seemingly unrelated estimation) command.58 Furthermore, to 
explore potential reasons for differences in sample and generalized treatment 
effects, we conducted a series of subgroup analyses in which we estimated 
treatment effects in subgroups that were over- or under-represented in the RCT 
samples compared to the target populations.  
Fourth, to directly compare the effects of the medications, we conducted an 
unweighted and weighted network meta-analysis of the four RCTs to estimate 
the comparative treatment effects across the four medications. Past research has 
shown that statistical precision of estimated treatment effects from network meta-
analyses are often better than that of estimated effects from pairwise 
comparisons in meta-analysis.109,110 Network meta-analysis also allows for 
determination of relative rankings of multiple treatments.111 We estimated fixed-
effect network meta-analysis models. 
 
4.4. Results 
Comparison of characteristics of four CTN trials and target populations 
Table 4.1. presents the comparison of characteristics between four RCTs 
and the TEDS-A target population. Overall, the RCT samples had significantly 
lower proportions of women, non-Hispanic White individuals, and patients 
younger than 35 years old than the TEDS-A; whereas, the RCT samples had 
significantly higher proportions of individuals with 12 or more years of education, 
individuals with fulltime jobs, married individuals, and individuals who used 
intravenous drugs than the TEDS-A. For all the RCTs, the proportions of patients 
with fulltime jobs were significantly higher than the TEDS-A.  
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Table 4.2. presents the comparison of characteristics between four RCTs 
and the NSDUH target population. Overall, the RCT samples had significantly 
lower proportions of women, individuals from non-Hispanic White racial-ethnic 
groups, and those younger than 35 years old than the NSDUH; whereas, the trial 




Table 4.3. presents the results of the analyses for the overall treatment 
effect on trial retention and abstinence. Odds ratios (ORs) and regression 
coefficients (βs) from both unweighted and weighted logistic and linear 
regression models, respectively, are presented with the 95% confidence 
intervals. The unweighted models estimated the overall treatment effect in the 
RCTs while the weighted models estimated the effects that would be expected if 
the distributions of characteristics in RCTs were similar to those in the target 
populations. In addition, the results of comparisons of regression coefficients are 
presented in Table 4.3. 
For retention, the overall population treatment effect was significantly larger 
for the analyses weighted by TEDS-A as well as NSDUH than the sample 
treatment effect (Table 4.3). An odds ratio of 1.76 suggests that individuals 
receiving the active pharmaceutical agents have 76% higher odds of being 
retained in the follow-up compared to those treated with placebo. In contrast, 
there was no statistically significant difference between the weighted effect and 
the unweighted effect on self-reported abstinence (Table 4.3).  
The results of subgroup analysis of treatment effects are presented in 
Appendix Table 4.2. We found some consistent patterns in the directions of 
change in outcomes through weighting and by subgroup analysis. For example, 
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the non-married individuals that were slightly underrepresented in the overall 
RCTs (p=0.10) showed evidence of larger treatment effects on retention than the 
overrepresented group of married individuals. Weighting the RCT samples to 
resemble the target populations increased the weights for the subsample of non-
married individuals which had larger treatment effect sizes, leading to a 
significantly larger treatment effect on retention after weighting of the data.  
 
Network meta-analysis 
Table 4.4. presents the results of network meta-analysis comparing the 
effect of the four medications on cocaine dependence. Odds ratios (ORs) and 
regression coefficients (βs) from both unweighted and weighted logistic or linear 
regression models, respectively, are presented with the 95% confidence 
intervals. We also present the relative rankings of the treatments, computed as 
the probabilities of each treatment being the best among all the treatments in the 
network meta-analysis. 
In unweighted model for each medication, there was no significant 
treatment effect. Although the 95% confidence intervals for the estimated 
treatment effects for each medication overlapped with each other, Buspirone was 
the most efficacious medication for retention and Modafinil was the most 
efficacious medication for abstinence. Weighting altered the relative ranking of 
the treatments. For retention, weighting by TEDS-A did not change the ranking 
while weighting by NSDUH made the second most efficacious treatment, 
Ondansetron, the most efficacious. For abstinence, the least efficacious 
treatment, Reserpine, became the second most efficacious after weighting for 
both target populations. Moreover, Ondansetron was the second most efficacious 
treatment for retention before weighting; however, it became the second least 
efficacious treatment after weighting.  
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Data from subgroup analyses presented in Appendix Table 4.2. suggest 
possible reasons for the changes in ranking of treatments. The married 
individuals that were overrepresented in the CTO0005 (Ondansetron trial) 
sample showed evidence of larger treatment effects on abstinence than 
overrepresented group of married individuals. Weighting the CTO0005 sample to 
resemble the target populations decreased the weights for subsample of married 
individuals with larger treatment effect sizes, leading to a smaller treatment effect 
on abstinence.  
 
4.5. Discussions 
This study showed that the findings from meta-analyses of cocaine 
dependence medications may not be directly applicable to potential target 
populations. The estimated overall target population-weighted treatment effect of 
four cocaine dependence medications on retention was significantly larger than 
the treatment effect from the RCTs whether the effect was generalized by the 
TEDS-A, representing the treatment-seeking target population of individuals with 
cocaine dependence, or by NSDUH, representing the target population of 
individuals with cocaine dependence in the community. Weighting the RCT 
samples to resemble target populations also altered the relative ranking of the 
efficacy across different medications. The results from the subgroup analysis of 
treatment effects partially explained these differences in effect estimates 
between unweighted meta-analysis and weighted meta-analyses.  
A study by Stuart et al.41 which used the same weighting-based approach 
to generalize the results of a school-based behavioral intervention trial found that 
the estimated population effect of intervention was slightly attenuated compared 
to the estimated sample effect from the RCT. In the context of SUD RCTs, a 
study by Susukida et al.73 demonstrated a statistically significant difference 
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between the sample treatment effect and the population treatment effect by 
applying the statistical weighing-based method to the ten CTN studies, which 
assessed efficacy of SUD treatments. To our knowledge, the present study is the 
first to perform a meta-analysis and network meta-analysis of multiple SUD 
treatments while using a weighting approach to enhance generalizability of the 
findings to the target populations. 
The findings from this study have implications for future meta-analyses of 
SUD treatments. As shown in this study, the overall treatment effect size and 
comparative effects changed when the deviations of each RCT sample from the 
target population were taken into account.  Unlike the previous study by 
Susukida et al.73 that found a decrease in treatment effect sizes after weighting of 
data from 10 SUD RCT samples, the effect size associated with the cocaine 
dependence medications on retention in the present study became significantly 
larger after weighting by population weights. This implies that the effect of 
weighting-based methods may vary depending on how and to what extent the 
composition of the RCT samples and target populations vary. Furthermore, 
differences in efficacies among different treatments for the same condition may 
be impacted by the compositions of the RCT samples for each treatment. Target 
population weighting of the RCTs changed the relative ranking of treatments for 
cocaine dependence in this study. This study also showed some suggestive 
evidence that the mechanisms through which the population treatment effects 
were different from the sample effects could be partially explained by treatment 
effect heterogeneity among under- or over-represented subgroups of individuals 
in the RCTs. 
Several limitations should be taken into account when interpreting the 
findings of this study. First, the number of characteristics recorded in both the 
clinical trial samples and the target populations was relatively small, which likely 
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limited our ability to account for potentially important treatment effect modifiers 
that may have been different between the RCTs and the target populations, such 
as motivation for treatment and severity of SUD. Second, the weighting-based 
approach might not have made the distributions of the clinical trial samples 
sufficiently close to the distributions of the target populations to estimate the 
population treatment effects because of the substantial differences between the 
clinical trial samples and the corresponding target populations. The weighting-
based method is more suitable to estimate the population treatment effect when 
the distributions of characteristics in RCTs overlap with those of the target 
populations, as they did in this study. Third, the present study could only show 
suggestive evidence of treatment effect heterogeneity across subgroups of 
individuals in the clinical trial samples because the CTN studies did not originally 
intend to assess the treatment effect heterogeneity and the subgroup analyses 
conducted here were not sufficiently powered. Fourth, there were substantial 
missing data in the TEDS-A which may have biased the results. Fifth, the number 
of trials included in this study was limited, which likely limited the reliability of the 
network meta-analysis 112 and our ability to conclude which medication is the 
most promising for treating cocaine dependence.  
Limitations notwithstanding, the findings of this study provide insight into 
the generalizability of meta-analysis of cocaine dependence medications. The 
overall population weighted effect on trial retention appears promising for four 
cocaine dependence medications (Reserpine, Modafinil, Buspirone, and 
Ondansetron). The relative ranking of effectiveness among the four treatments 
was altered when we considered generalizability of the findings to the target 
populations. Modafinil appears to be the most promising treatment among these 
four medications, although both the sample treatment effect and the target 
population-weighted effects were statistically nonsignificant. With the growing 
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number of RCTs for cocaine dependence medications, future meta-analytic 
studies should assess overall treatment effects as well as comparative 
effectiveness while considering generalizability to target populations. The 
weighting-based approach used in this study is applicable to meta-analyses of 
clinical trials of other SUD treatments, as well as other health interventions, 
especially when generalizability of the findings is a concern. Although an 
increasing number of clinical trials for SUD treatments use less stringent 
inclusion and exclusion criteria, reducing concerns about generalizability of 
findings,37 it may not always be possible to recruit samples that are fully 
representative of the target populations, e.g., when there are safety concerns for 
certain population subgroups. In these circumstances, the weighting-based 
method used in this study could be useful to assess applicability of the findings to 
treatment seeking target populations or to all individuals with the health condition 
of interest in the general community.  
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  %  % % % % % 
Sex         
Female  42.3  27.9 29.4 28.1 37.1 15.4 
Race         
White  41.2  27.4 18.8 29.2 25.8 38.5 
Age         
<35  33.8  19.1 22.7 14.3 6.5 40.0 
Education         
≥12 years  66.4  82.8 84.9 89.5 64.5 81.5 
Employment         
Full-time  9.2  33.8 31.1 32.4 21.0 55.4 
Marital Status         
Married  12.3  23.3 19.5 26.2 12.9 30.8 
IV drug use         






    
Yes  64.3  61.0 57.6 58.6 100.0 37.5 
a. Pearson’s χ2 test was conducted. Numbers shown in bold type indicate statistically significant 
differences between RCT and TEDS-A samples at P < 0.05
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%  % % % % % 
Sex        
Female 37.4  27.9 29.4 28.1 37.1 15.4 
Race        
White 52.8  27.4 18.8 29.2 25.8 38.5 
Age        
<35 49.9  19.1 22.7 14.3 6.5 35.3 
Education        
≥12 years 79.4  82.8 84.9 89.5 64.5 81.5 
Employment        
Full-time 33.7  33.8 31.1 32.4 21.0 55.4 
Marital Status        
Married 15.5  23.3 19.5 26.2 12.9 30.8 
IV drug use        





    
Yes 65.5  61.0 57.6 58.6 100.0 37.5 
a. Pearson’s χ2 test was conducted. Numbers shown in bold type indicate statistically significant differences between 
RCT and NSDUH samples at P < 0.05. 
b. The sampling weight was taken into consideration for the NSDUH target population. 
 
 72 
Table 4.3. Unweighted and weighted meta-analysis of pharmacological cocaine dependence treatments with two target 
populations 
Target population = TEDS-A 
Outcome Unweighted OR 95%CI Weighted OR  95%CI Statistics for difference 
Retention 1.36** 1.14, 1.62 1.76** 1.30, 2.38 2 =5.48, p= 0.02 
Outcome Unweighted β 95%CI Weighted β  95%CI Statistics for difference 
Abstinence -0.81 -3.10, 1.48 -1.27 -2.76, 0.23 2 =1.01, p=0.31 
Target population = NSDUH 
Outcome Unweighted OR 95%CI Weighted OR  95%CI Statistics for difference 
Retention 1.36** 1.14, 1.62 2.74** 1.54, 4.88 2 =5.99, p= 0.01 
Outcome Unweighted β 95%CI Weighted β  95%CI Statistics for difference 
Abstinence  -0.81 -3.10, 1.48 -0.84 -3.12, 1.44 2 =0.00, p=0.98 
Note: Weighted results were weighted by the TEDS-A and NSDUH target populations. 
We estimated multi-level mixed effect models, which allow random intercepts and a 
coefficient on treatment assignment variable. The standard errors were clustered at 
the trial level. The weight was truncated at 95 percentiles to eliminate extreme weights. 













Table 4.4. Unweighted and weighted network meta-analysis of four pharmacological treatments for cocaine dependence. 
Retention 
 Unweighted  Weighted (with TEDS-A) Weighted (with NSDUH) 
 OR  95%CI  Rank 
(%) 
OR  95%CI  Rank 
(%) 
OR  95%CI  Rank 
(%) 
Reserpine vs. Placebo 1.10 0.27, 1.94 5.4% 1.28 -0.31, 2.85 2.6% 1.97 0.48, 8.17 2.9% 
Modafinil vs. Placebo 1.47 0.58, 2.36 17.7% 1.66 0.15, 3.18 4.7% 2.19 0.78, 6.17 1.9% 
Buspirone vs. Placebo 1.84 -1.11, 
4.79 











 Unweighted  Weighted (with TEDS-A) Weighted (with NSDUH) 
 Coefficient  95%CI  Rank 
(%) 
Coefficient  95%CI  Rank 
(%) 
Coefficient  95%CI  Rank 
(%) 
Reserpine vs. Placebo -2.63 -6.21, 
0.94 
2.3% -2.13 -7.42, 3.16 15.0% -1.43 -8.16, 
5.34 
23.0% 
Modafinil vs. Placebo 1.14 -1.63, 
3.90 
61.9% -0.09 -3.95, 3.78 40.0% 0.75 -3.44, 
4.92 
50.3% 
Buspirone vs. Placebo -2.15 -5.50, 
1.21 







20.6% -5.05 -13.41, 
3.24 
8.5% -4.07 -9.24, 
1.12 
2.6% 
Note: Weighted results were weighted by the TEDS-A and NSDUH target populations. The weight was truncated at 95 percentiles to eliminate extreme weights. Rank (%) 
represents the estimated probability of each medication being the most efficacious medication among four medications. ** p<0.01, * p<0.05 
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CHAPTER 5 Conclusions and Policy Implications 
5.1. Summary of main findings 
The purpose of this dissertation was to assess generalizability of findings of 
various SUD RCTs to intended target populations. The Chapter 2 aimed to 
generalize the treatment effects estimated through SUD RCTs to intended target 
populations by comparing RCT sample treatment effects and the population 
effects of SUD treatment. In Chapter 2, we generalized three outcomes 
(retention, urine toxicology and abstinence) from ten RCTs from the NIDA CTN 
studies (five trials of Buprenorphine/Naloxone detoxification for opioid 
dependence, three trials of motivational enhancement/interviewing on SUD, and 
two trials of motivational incentives for cocaine, methamphetamine or 
amphetamine use) to the target populations of treatment-seeking individuals 
drawn from the TEDS-A. We demonstrated that the observed outcomes of some 
RCTs may not be directly applicable to potential target populations. Statistically 
significant treatment effects estimated in the RCT samples became insignificant 
when they were weighted to the target population in most cases (three trials for 
retention and urine toxicology, and one trial for abstinence); but also we found 
that insignificant effects became significantly positive (in one trial for abstinence 
as an outcome), and significantly negative effects became insignificant (in two 
trials for abstinence as an outcome). We also presented suggestive evidence 
that these differences in effect estimates between the unweighted and weighted 
models could be partially explained by treatment effect heterogeneity across 
over- and under- represented subgroups of the RCT participants as compared 
with the target populations.  
The Chapter 3 aimed to assess the generalizability of the findings from a 
multi-site web-based SUD intervention to two different types of target 
populations. In that chapter, we generalized two outcomes (retention and 
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abstinence) of the RCT sample of a web-based SUD intervention, the 
Therapeutic Education System (TES), to two types of target populations: SUD 
treatment-seeking individuals drawn from the TEDS-A and community-dwelling 
individuals with recent substance use, whether or not they sought treatment, 
drawn from the NSDUH. We first demonstrated significant differences between 
the RCT sample and target populations of potential recipients of the intervention. 
As compared with the TEDS-A target population, the RCT sample had 
significantly lower proportions of Hispanic individuals, those with a history of 
intravenous drug use, and those with history of prior SUD treatment while the 
RCT sample had significantly higher proportions of those with 12 years or longer 
of education and those with full time jobs. As compared with the NSDUH target 
population, the RCT sample had significantly lower proportions of individuals 
between age 18-34 years, those with 12 years or longer of education, individuals 
with fulltime jobs, married individuals, and those with a history of prior SUD 
treatment while the RCT sample had significantly higher proportions of Blacks, 
those between age 35-49 years, and those with intravenous drug use. Moreover, 
we showed that the summary index of these differences, p, was much larger 
than the standardized p cutoff 0.2529–31 or 0.1032 for both target populations 
(1.62 and 1.14 standard deviations for the TEDS-A and NSDUH, respectively), 
indicating substantial differences between the RCT sample and the target 
populations. Finally, these analyses showed that the observed promising findings 
of the TES intervention may not be directly generalizable to potential target 
populations. We found that significant treatment effects on abstinence at 12 
weeks and 6-month follow-up became insignificant after weighting. We also 
showed some suggestive evidence that these differences between the 
unweighted sample treatment effects and the estimated population effects could 
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be partially explained by the treatment effect heterogeneity across under- and 
over-represented subgroups of RCT participants.  
The Chapter 4 aimed to conduct a meta-analysis of RCTs of cocaine 
dependence medications as well as a network meta-analysis to compare the 
effects of multiple treatments of cocaine dependence while considering 
generalizability of the findings of the RCTs to the target populations and adjusting 
the results to make them more generalizable. In Chapter 4, we generalized two 
outcomes (retention and abstinence) of four RCTs (Reserpine, Modafinil, 
Buspirone, and Ondansetron vs. placebo) drawn from the NIDA CTN to two 
types of target populations: treatment-seeking individuals with cocaine 
dependence drawn from the TEDS-A and community-dwelling individuals with 
cocaine dependence, regardless of their treatment seeking behaviors, drawn 
from the NSDUH. We found that the results from meta-analyses of cocaine 
dependence medications may not directly carry over to potential target 
populations. The estimated overall target population-weighted treatment effect of 
four cocaine dependence medications on retention was significantly larger than 
the treatment effect from the RCTs whether the effect was generalized by the 
TEDS-A or by NSDUH. Weighting the RCT samples to resemble target 
populations also changed the relative ranking of the treatment effectiveness 
across different medications. For retention, the second most efficacious 
treatment, Ondansetron, became the most efficacious after applying NSDUH 
generalizability weights. For abstinence, the least efficacious treatment, 
Reserpine, became the second most efficacious after weighting for both target 
populations. The results from the subgroup analysis of treatment effects partially 
explained these differences in effect estimates between unweighted meta-
analysis and weighted meta-analyses.  
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5.2. Synthesis of findings 
This dissertation applied the propensity score based weighting method to 
the context of SUD RCTs. Stuart et al.41 generalized the results of a school-
based behavioral intervention trial with propensity score-based weighting and 
found that the estimated population effect of intervention was slightly attenuated 
compared to the estimated sample effect from the RCT. The findings of this 
dissertation have implications for the external validity of results from SUD RCTs. 
Previous studies suggested that stringent eligibility criteria of SUD RCTs would 
create a substantial selection bias in RCT samples.11 Furthermore, a recent 
study by Susukida et al.12 showed substantial variability in the likelihood of being 
in RCT samples across patient subgroups by using the actual samples of RCTs 
and indicated that poor representation of target populations might impact the 
generalizability of findings from RCTs. The results of Chapter 2 confirm this 
prediction by showing differences in the statistical significance between the 
sample treatment effects and the population treatment effects with the data of ten 
RCT samples (five trials of Buprenorphine/Naloxone detoxification for opioid 
dependence, three trials of motivational enhancement/interviewing on SUD, and 
two trials of motivational incentives for cocaine, methamphetamine or 
amphetamine use). Chapter 2 also demonstrated suggestive evidence that 
treatment effect heterogeneity among under- or over-represented subgroups of 
patients in the RCTs could partially explain why the population treatment effects 
estimated by weighting the RCT samples differed from the sample effects.  
Similar findings were shown in the context of a web-based SUD 
intervention (the Therapeutic Education System; TES) in Chapter 3. Whether the 
target population consisted of treatment-seeking individuals with recent drug use 
(TEDS-A) or individuals with recent drug use regardless of treatment seeking 
status (NSDUH), the composition of the RCT sample of the TES substantially 
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differed from those of the target populations. The findings of Chapter 3 indicated 
that the promising treatment effects of the TES intervention estimated through 
RCTs may not be directly generalizable to both types of target populations. 
Chapter 3 also demonstrated some suggestive evidence that these differences 
between the unweighted sample treatment effects and the estimated population 
effects could be partially explained by the treatment effect heterogeneity across 
under- and over-represented subgroups of RCT participants. Regarding the 
generalizability of the findings of a web-based SUD intervention, this study’s 
findings echo the findings of the recent study by Blanco et al.,27 which found the 
significant treatment effect of TES estimated through RCT became insignificant 
after weighting the sample to resemble the target populations drawn from 2000-
2001 NESARC data. Our study confirms that their findings hold when the 
generalizability of the TES RCT was assessed with the target populations from 
recent years.  
To our knowledge, Chapter 4 was the first study to conduct a meta-analysis 
and network meta-analysis of multiple SUD treatments while using a weighting 
approach to enhance generalizability of the findings to the target populations. 
The findings from Chapter 4 have implications for future meta-analyses of SUD 
treatments. As shown in this study, the overall treatment effect size and 
comparative effects changed when the deviations of each RCT sample from the 
target population were taken into account.  Unlike Chapter 2, which found a 
decrease in treatment effect sizes after weighting of data from ten SUD RCT 
samples, the effect size associated with the cocaine dependence medications on 
retention became significantly larger after weighting by population weights. This 
implies that the effect of weighting-based methods may vary depending on how 
and to what extent the composition of the RCT samples and target populations 
vary. Furthermore, differences in efficacies among different treatments for the 
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same condition may be impacted by the compositions of the RCT samples for 
each treatment. Target population weighting of the RCTs changed the relative 
ranking of treatments for cocaine dependence in this study. This study also 
showed some suggestive evidence that the mechanisms through which the 
population treatment effects were different from the sample effects could be 
partially explained by treatment effect heterogeneity among under- or over-
represented subgroups of individuals in the RCTs. 
 
5.3. Strengths and limitations of these findings  
The results of this dissertation should be interpreted in light of certain 
strengths as well as limitations. Although a growing number of studies suggest 
that stringent eligibility criteria commonly used in RCTs of SUD treatment would 
create a substantial selection bias in the RCT samples, which may adversely 
impact generalizability of the findings from SUD RCTs, very few previous studies 
have examined generalizability of findings of actual SUD RCTs to the intended 
target populations. A major strength of this dissertation was its use of actual RCT 
samples of various trials of SUD interventions to assess generalizability of the 
findings of these RCTs to differently defined target populations by applying a 
novel approach with propensity score-based weighting.  
The following are several limitations of this dissertation. First, the number 
of characteristics measured in both the RCT samples and the target populations 
was limited. Therefore, it is likely that weights calculated in this study could not 
take into account other characteristics which may have differed between the RCT 
samples and target populations and also contributed to treatment heterogeneity. 
Second, due to the significant differences between the RCT samples and their 
target populations, the weighting-based method may not have made the RCT 
samples adequately resemble the target populations to estimate the population 
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treatment effects. Weighting the RCT samples to estimate the population 
treatment effects is more suitable when the RCT samples and the target 
populations are more similar to start with. Third, the primary goal of the original 
RCTs was not to assess treatment effect heterogeneity. Hence, the subgroup 
analyses conducted for this study were not adequately powered and the findings 
only provide suggestive evidence of treatment effect heterogeneity across 
subgroups of patients. Fourth, one of the data sources of our target population, 
TEDS-A data missed some groups of patients. Therefore, the population 
treatment effects estimated by this study may not represent treatment effects 
among all recipients of SUD treatment in the US. Although the TEDS-A is one of 
the largest administrative data sources that cover the data on most patients with 
SUD in the US, some states exclude patients whose treatment is not covered by 
the state substance use agency funds such as Federal Block Grant funds.44 
Patients who received treatment at private hospitals are usually excluded from 
the TEDS-A unless they have licenses from the state substance abuse treatment 
agency. Therefore, the TEDS-A might not have represented the entire population 
of patients with SUD in the US. Fifth, the RCT sample of a web-based SUD 
intervention in Chapter 3 was collected in clinical (outpatient) settings. Due to its 
potential scalability, a web-based intervention could be implemented in non-
clinical settings such as school or community settings; therefore, the applicability 
of the findings of Chapter 3 might be limited to the context of the web-based SUD 
RCTs in clinical settings only. Sixth, the number of trials included in Chapter 4 
was limited, which may have limited the reliability of the network meta-analysis112 
to draw conclusions regarding which cocaine dependence treatment was more 




Acknowledging these limitations, results from this dissertation provide 
insight into whether and how deviations in RCT sample representativeness from 
target populations influence the observed outcomes of various SUD RCTs. As 
interest in comparative effectiveness research in real-world treatment settings 
increases, RCTs for mental health treatments increasingly use less stringent 
eligibility criteria for participation, which may improve generalizability of the 
findings of RCTs.37 However, relaxing eligibility criteria may not be feasible for all 
RCTs, especially when there are safety concerns for patients such as allergic 
reactions to certain medications. In such cases, the weighting-based method that 
this study employed might be useful to examine to what extent the findings of 
RCTs are applicable to target populations. As attention to large-scale 
dissemination and implementation of evidence-based treatments and 
interventions increases,36 it becomes increasingly important to understand the 
applicability of the findings of RCTs in different populations with varying 
characteristics, contexts, and locations. Particularly given the potential scalability 
of web-based SUD interventions,34 representativeness of the sample with regard 
to target populations of potential users of this intervention should be carefully 
considered. As a growing number of RCTs of SUD treatments are implemented 
in various settings, future meta-analytic studies should estimate treatment effects 
as well as comparative effectiveness while accounting for generalizability to 
intended target populations. The weighting-based approach used in this study is 
applicable to meta-analyses of clinical trials of other SUD treatments, as well as 
other health interventions, especially when generalizability of the findings is a 
concern. It is also important to consider the change in the nature of target 
populations especially in the context of the United States, where more people are 
eligible for health insurance as a part of Affordable Care Act legislation,59 which 
may affect profiles of patient groups who seek and access treatments.  
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Appendix Table 2.1. Comparison of baseline characteristics (%) of the samples in ten National Institute of Drug 
Abuse Clinical Trial Network (CTN) studies and target samples from the Treatment Episodes Data-Admission 
(TEDS-A). 
1Pearson chi-square test was conducted. Numbers written in bold letters indicate statistically significant differences between RCT 
and TEDS-A samples at p<.05. 
2 Not included in the analyses as these variables were not available for CTN0010. 
3 Not included in the analyses because of a large number of missing values for this variable in TEDS-A.
 Buprenorphine/Naloxone (Bup/Nx) Detoxification Motivational enhancement/interviewing Motivational incentives 
 CTN0001 CTN0002 CTN0003 CTN0010 CTN0030 CTN0004 CTN0005 CTN0013 CTN0006 CTN0007 
RCT TEDS RCT TEDS RCT TEDS RCT TEDS RCT TEDS RCT TEDS RCT TEDS RCT TEDS RCT TEDS RCT TEDS 
Total number 113 3,111 230 57,959 516 157,619 154 22,588 653 260,754 461 520,636 423 258,887 200 57,526 454 213,869 388 49,277 
Sex                     
Female 39.81 25.9 28.3 38.2 32.8 39.4 41.6 32.4 39.9 44.3 29.1 35.6 42.1 35.4 100.0 100.0 54.9 38.7 45.1 40.8 
Race                     
White 55.8 52.5 40.0 53.2 71.1 57.6 70.1 69.4 91.0 68.5 42.0 62.9 71.9 62.2 37.2 58.0 35.7 54.4 24.9 50.4 
Age                       
 ≥ 35  55.8 48.0 66.9 51.2 54.3 48.0 0.0 0.0 37.8 46.2 55.7 45.2 44.7 45.5 9.5 15.4 59.3 48.7 85.2 56.7 
Education                      
≥12 years 87.6 63.0 73.5 63.5 84.3 61.8 51.9 28.5 84.4 66.7 80.5 63.4 76.4 62.7 54.5 54.4 66.5 62.2 64.5 61.3 
Employment                      
Full-time 58.0 5.6 54.3 22.5 58.9 18.6 --2 --2 63.1 16.1 58.8 24.3 57.4 25.5 32.5 8.6 48.2 20.6 31.7 14.6 
Marital Status                     
Married  33.6 12.8 24.3 18.5 30.2 17.8 14.3 1.9 28.7 17.7 18.4 16.8 19.9 16.9 14.5 16.7 23.3 16.2 14.0 14.8 
Criminal justice admission                      
Yes  8.9 3.9 3.1 31.6 2.5 28.5 --2 --2 0.5 18.7 32.2 35.8 53.2 35.6 13.0 31.4 35.9 30.9 5.0 17.7 
IV drug use                      
Yes  31.1 18.5 26.7 26.0 26.3 29.7 --2 --2 3.4 36.8 6.0 20.0 16.3 20.5 2.8 16.3 9.3 22.2 35.6 52.5 
# prior treatments                      
≥ 5 times --3 --3 15.4 6.1 20.4 7.7 --2 --2 4.1 11.6 24.1 13.6 9.0 13.9 11.4 7.3 19.1 14.6 42.6 23.0 
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Appendix Table 2.2. Types of subgroup analyses 
CTN trial Outcome Characteristics identifying subgroups 
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Appendix Table 2.3. Results of the subgroup analysis of treatment effects 
  Retention (end of trial) Urine tox (end of trial) Abstinence  (follow-up 1) 
  T C Test Interaction T C Test Interaction T C Test Interaction 
Study Variable              
CTN0001 Sex             
 Men  - - - - - - - - 25.6 22.7 t=-0.9 -- 
 Women  - - - - - - - - 25.3 15.4 t=-2.6 p=0.16 
 Education             
 < 12 years - - - - - - - - 26.2 30.0 t=0.9 -- 
 ≥ 12 years - - - - - - - - 25.4 17.8 t=-2.9 p=0.15 
 Employment              
 Full-time - - - - - - - - 24.4 19.2 t=-1.5 -- 
 Other - - - - - - - - 27.3 21.3 t =-1.9 p=0.87 
 Marital status             
 Married - - - - - - - - 25.8 15.0 t=-2.1 -- 
 Non-married - - - - - - - - 25.3 20.4 t=-1.8 p=0.29 
 Criminal justice             
 Yes  - - - - - - - - 29.2 30.0 t=1.2 -- 
 No - - - - - - - - 25.0 16.3 t=-3.2 p=0.15 
 IV drug use              
 Yes - - - - - - - - 25.2 16.7 t=-1.7 -- 
 No - - - - - - - - 25.5 20.1 t =-1.9 p=0.57 
CTN0002 Sex             
 Men  56.1 31.4 χ12=8.7 -- - - - - 18.9 17.4 t=-0.5 -- 
 Women  57.1 17.4 χ12=9.6 p=0.26 - - - - 16.9 10.9 t=-1.4 p=0.39 
 Race             
 White  54.8 26.7 χ12=6.5 -- - - - - 18.3 19.3 t=0.2 -- 
 Non-White 57.5 27.3 χ12=10.9 p=0.91 - - - - 18.3 13.5 t=-1.5 p=0.28 
 Age             
 < 35 46.3 13.6 χ12=7.2 -- - - - - 16.8 14.8 t=-0.3 -- 
 ≥ 35 61.8 32.7 χ12=11.7 p=0.52 - - - - 19.0 15.3 t=-1.4 p=0.81 
 Education             
 < 12 years 55.0 14.3 χ12=9.4 -- - - - - 16.4 12.0 t=-0.8 -- 
 ≥ 12 years 56.9 32.1 χ12=9.0 p=0.22 - - - - 18.8 16.4 t=-0.9 p=0.74 
 Employment              
 Full-time 59.5 34.2 χ12=7.1 -- - - - - 19.9 17.3 t=-0.9 -- 
 Other 52.8 18.2 χ12=11.1 p=0.38 - - - - 16.5 10.3 t=-1.4 p=0.48 
 Marital status             
 Married 58.6 14.3 χ12=4.4 -- - - - - 17.8 16.0 --1 -- 
 Non-married 55.9 28.4 χ12=13.4 p=0.41 - - - - 18.4 15.2 t=-1.2 p=0.90 
 Criminal justice             
 Yes  83.3 0.0 χ12=2.9 -- - - - - 16.7 --3 --3 -- 
 No 55.0 27.8 χ12=14.5 --2 - - - - 18.5 15.2 t=-1.3 --3 
 Prior treatment              
 < 5 56.6 29.8 χ12=11.5 -- - - - - 18.5 15.6 t=-1.1 -- 
 ≥ 5 55.0 17.7 χ12=5.5 p=0.47 - - - - 17.1 13.0 t=-0.6 p=0.87 
CTN0003 Sex             
 Men 76.2 63.4 χ12=6.7 -- 42.4 29.7 χ12=6.1 -- - - - - 
 Women 84.3 66.3 χ12=7.4 p=0.38 47.0 30.2 χ12=5.0 p=0.69 - - - - 
 Race             
 White  78.1 60.3 χ12=13.6 -- 42.3 26.3 χ12=10.4 -- - - - - 
 Non-White 80.9 72.8 χ12=1.3 p=0.39 48.5 37.0 χ12=2.0 p=0.54 - - - - 
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 Age             
 < 35 79.2 61.2 χ12=9.1 -- 40.0 27.6 χ12=4.1 -- - - - - 
 ≥ 35 78.5 66.9 χ12=4.7 p=0.48 47.4 31.7 χ12=7.2 p=0.78 - - - - 
 Education             
 < 12 years 75.6 60.0 χ12=2.3 -- 43.9 32.5 χ12=1.1 -- - - - - 
 ≥ 12 years 79.4 65.2 χ12=11.0 p=0.99 43.9 29.1 χ12=9.9 p=0.77 - - - - 
 Employment              
 Full-time 77.8 60.7 χ12=12.2 -- 47.7 27.7 χ12=12.8 -- - - - - 
 Other 80.2 72.6 χ12=1.7 p=0.24 38.7 33.0 χ12=0.7 p=0.10 - - - - 
 Marital status             
 Married 79.8 63.9 χ12=4.9 -- 46.4 37.5 χ12=1.3 -- - - - - 
 Non-married 78.4 64.6 χ12=8.3 p=0.80 42.7 27.0 χ12=9.8 p=0.40 - - - - 
 Criminal justice             
 Yes  100.0 62.5 χ12=2.4 -- 40.0 12.5 χ12=1.3 -- - - - - 
 No 78.4 64.4 χ12=12.0 p=0.98 44.0 30.4 χ12=9.9 p=0.50 - - - - 
 Prior treatment              
 < 5 76.9 66.0 χ12=5.9 -- 44.7 31.1 χ12=8.1 -- - - - - 
 ≥ 5 85.7 57.1 χ12=10.7 p=0.07 41.1 24.5 χ12=3.2 p=0.70 - - - - 
CTN0010 Sex             
 Men  78.6 56.3 χ12=5.0 p=0.83 62.5 15.6 χ12=14.8 p=0.30 22.0 20.8 t=-0.4 p=0.24 
 Women  78.1 59.4 χ12=2.6 -- 54.8 22.9 χ12=9.7 -- 18.1 22.6 t=1.2 -- 
 Education             
 < 12 years 69.9 55.3 χ12=1.6 -- 47.2 13.2 χ12=10.3 -- 20.5 19.7 t=-1.2 -- 
 ≥ 12 years 86.8 59.5 χ12=7.5 p=0.24 68.4 26.2 χ12=14.3 p=0.97 20.5 22.7 t=0.8 p=0.50 
 Marital status             
 Married 71.4 40.0 χ12=1.9 -- 28.6 0.0 χ12=4.7 -- 29.2 18.5 t=-2.3 -- 
 Non-married 79.1 61.5 χ12=4.9 p=0.67 61.2 24.6 χ12=18.1 p=0.99 19.2 22.3 t=1.2 p=0.03 
CTN0030 Sex             
 Men  - - - - - - - - 18.4 21.2 t=2.5 -- 
 Women  - - - - - - - - 18.8 19.5 t=0.5 p=0.21 
 Race             
 White  - - - - - - - - 18.5 20.3 t=2.2 -- 
 Non-White - - - - - - - - 19.9 21.2 t=0.5 p=0.84 
 Age             
 < 35 - - - - - - - - 18.2 20.3 t=2.2 -- 
 ≥ 35 - - - - - - - - 19.3 20.5 t=0.8 p=0.55 
 Education             
 < 12 years - - - - - - - - 18.2 20.9 t=1.6 -- 
 ≥ 12 years - - - - - - - - 18.7 20.3 t=1.8 p=0.59 
 Employment              
 Full-time - - - - - - - - 18.6 20.8 t=2.0 -- 
 Other - - - - - - - - 18.5 19.9 t=1.1 p=0.67 
 Marital status             
 Married - - - - - - - - 17.7 19.8 t=1.3 -- 
 Non-married - - - - - - - - 19.0 20.7 t=1.9 p=0.84 
 Criminal justice             
 Yes  - - - - - - - - 25.0 11.0 --4 -- 
 No - - - - - - - - 18.7 20.4 t=2.1 p=0.18 
 IV drug use              
 Yes - - - - - - - - 15.1 19.9 t=1.2 -- 
 No - - - - - - - - 18.8 20.4 t=2.0 p=0.44 
 Prior treatment              
 < 5 - - - - - - - - 18.9 20.2 t=1.6 -- 




































1: There was only one observation in the control arm and it was not possible to calculate t-statistics.  
2: There was no observations in the control arm and it was not possible to estimate a coefficient for interaction term.  
3: There was no observations in the control arm and it was not possible to calculate the mean, t-statistics p-value for interaction term. 







CTN0004 Sex             
 Men  - - - - - - - - 25.3 27.2 t=2.0 -- 
 Women  - - - - - - - - 22.6 26.3 t=1.8 p=0.36 
 Race             
 White  - - - - - - - - 24.2 26.3 t=1.5 -- 
 No-White - - - - - - - - 24.8 27.3 t=2.3 p=0.86 
 Education             
 < 12 years - - - - - - - - 24.1 26.8 t=1.2 -- 
 ≥ 12 years - - - - - - - - 24.5 27.0 t=2.6 p=0.93 
 Employment              
 Full-time - - - - - - - - 25.9 27.3 t=1.3 -- 
 Other - - - - - - - - 22.2 26.5 t=2.9 p=0.10 
 IV drug use              
 Yes - - - - - - - - 22.6 25.8 t=0.6 -- 
 No - - - - - - - - 24.3 26.8 t=2.7 p=0.89 
 Prior treatment              
 < 5 - - - - - - - - 24.2 27.2 t=3.0 -- 
 ≥ 5 - - - - - - - - 25.0 26.2 t=0.6 p=0.40 
CTN0006 Sex             
 Men  41.5 34.3 χ12=1.1 -- 37.7 33.3 χ12=0.4 -- - - - - 
 Women  46.8 31.7 χ12=6.0 p=0.39 37.3 25.2 χ12=4.2 p=0.35 - - - - 
 Race             
 White  50.0 30.7 χ12=6.2 -- 44.6 25.0 χ12=6.9 -- - - - - 
 Non-White 41.8 34.3 χ12=1.7 p=0.22 34.2 31.3 χ12=0.3 p=0.07 - - - - 
 Age             
 < 35 52.7 30.4 χ12=9.4 -- 45.2 27.2 χ12=6.5 -- - - - - 
 ≥ 35 34.6 38.9 χ12=0.5 p=0.06 32.4 30.0 χ12=0.2 p=0.10 - - - - 
 Employment              
 Full-time 42.8 34.0 χ12=14.2 -- 41.8 27.5 χ12=4.9 -- - - - - 
 Other 42.6 34.5 χ12=1.6 p=0.24 33.6 30.1 χ12=0.3 p=0.24 - - - - 
 Marital status             
 Married 52.3 29.0 χ12=5.9 -- 45.5 25.8 χ12=4.4 -- - - - - 
 Non-married 42.6 34.4 χ12=2.4 p=0.17 35.6 30.0 χ12=1.2 p=0.20 - - - - 
 IV drug use              
              
 Yes 42.9 33.3 χ12=0.4 -- 37.1 29.4 χ12=2.8 -- - - - - 
 No 44.8 32.8 χ12=6.1 p=0.17 42.9 23.8 χ12=1.7 p=0.46 - - - - 
 Prior treatment              
 < 5 42.8 31.6 χ12=4.8 -- 36.4 27.7 χ12=3.1 -- - - - - 
 ≥ 5 50.0 36.4 χ12=1.6 p=0.19 45.2 31.8 χ12=1.6 p=0.30 - - - - 
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Appendix Table 3.1. Results of subgroup analysis of treatment effects 
 Retention (12 weeks) Abstinence  (12 weeks) Retention (3 months) Abstinence  (3 months) Retention (6 months) Abstinence  (6 months) 
 T C Test T*X1 T C Test T*X T C Test T*X T C Test T*X T C Test T*X T C Test T*X 
Variable                          
Sex                         
Men  85.4 84.8 χ12=0.0 -- 60.0 46.1 χ12=5.2 -- 87.8 90.1 χ12=0.4 -- 54.2 47.1 χ12=1.4 -- 50.0 48.3 χ12=0.1 -- 25.6 13.7 χ12=3.4 -- 
Women  86.8 90.1 χ12=0.5 p=0.50 54.4 44.0 χ12=1.9 p=0.72 86.8 95.1 χ12=4.0 p=0.20 48.1 49.0 χ12=0.0 p=0.41 60.4 60.4 χ12=0.0 p=0.86 21.8 13.1 χ12=1.5 p=0.81 
Race                         
White 81.3 85.6 χ12=1.0 -- 54.9 50.4 χ12=0.5 -- 84.2 90.2 χ12=2.4 -- 49.6 48.6 χ12=0.0 -- 58.3 51.6 χ12=1.3 -- 29.6 17.7 χ12=3.1 -- 
Non-White 91.9 88.9 χ12=0.5 p=0.24 59.8 37.5 χ12=9.4 p=0.07 91.9 95.0 χ12=0.8 p=0.95 54.9 46.8 χ12=1.3 p=0.46 50.5 55.6 χ12=0.5 p=0.19 16.1 7.3 χ12=2.1 p=0.76 
Age                         
< 35 81.8 85.0 χ12=0.5 -- 51.5 45.1 χ12=0.9 -- 88.9 92.5 χ12=1.0 -- 49.1 43.1 χ12=0.9 -- 55.6 58.7 χ12=0.3 -- 24.3 12.8 χ12=3.3 -- 
≥ 35 89.9 89.1 χ12=0.0 p=0.55 63.8 45.3 χ12=7.7 p=0.20 86.1 91.6 χ12=1.9 p=0.82 55.0 53.2 χ12=0.1 p=0.65 51.9 47.1 χ12=0.6 p=0.37 23.9 14.3 χ12=1.8 p=0.82 
Education                         
< 12 years 85.0 93.1 χ12=2.0 -- 62.8 38.9 χ12=6.0 -- 81.7 96.6 χ12=6.7 -- 42.9 41.1 χ12=0.0 -- 55.0 65.5 χ12=1.4 -- 24.2 13.2 χ12=1.5 -- 
≥ 12 years 86.2 85.1 χ12=0.1 p=0.17 56.6 47.3 χ12=2.9 p=0.19 89.2 90.7 χ12=0.2 p=0.05 54.6 50.0 χ12=0.7 p=0.81 53.3 49.5 χ12=0.6 p=0.17 24.0 13.5 χ12=3.6 p=0.95 
Employment                          
Full-time 89.3 84.0 χ12=1.1 -- 62.9 50.0 χ12=2.6 -- 92.2 93.0 χ12=0.0 -- 57.9 52.7 χ12=0.5 -- 50.5 43.0 χ12=1.1 -- 26.9 18.6 χ12=0.9 -- 
Other 83.6 88.8 χ12=1.8 p=0.10 55.1 42.2 χ12=4.4 p=0.94 84.2 91.5 χ12=3.7 p=0.37 47.7 44.6 χ12=0.2 p=0.82 55.9 59.9 χ12=0.5 p=0.21 22.4 11.0 χ12=4.1 p=0.57 
Marital status                         
Married 88.9 83.3 χ12=0.5 -- 62.5 40.0 χ12=3.1 -- 94.4 91.7 χ12=0.2 -- 55.9 57.6 χ12=0.0 -- 47.2 58.3 χ12=0.9 -- 35.3 19.1 χ12=1.3 -- 
Non-married 85.4 87.5 χ12=0.4 p=0.39 57.2 46.0 χ12=4.7 p=0.41 86.3 92.1 χ12=3.8 p=0.29 51.3 46.2 χ12=1.0 p=0.61 54.8 52.3 χ12=0.3 p=0.29 22.5 12.4 χ12=4.1 p=0.88 
IV drug use                          
Yes 75.0 88.9 χ12=1.2 -- 46.7 62.5 χ12=0.8 -- 70.0 100.0 χ12=6.4 -- 57.1 55.6 χ12=0.0 -- 40.0 50.0 χ12=0.4 -- 25.0 33.3 χ12=0.1 -- 
No 86.8 86.8 χ12=0.0 p=0.30 58.8 43.8 χ12=9.1 p=0.10 88.9 91.5 χ12=0.8 --2 51.7 47.2 χ12=0.8 p=0.88 54.9 53.4 χ12=0.1 p=0.50 24.0 12.0 χ12=0.2 p=0.27 
Prior 
treatment  
                        
Yes  90.0 84.2 χ12=0.3 -- 44.4 37.5 χ12=0.2 -- 95.0 79.0 χ12=2.2 -- 42.1 53.3 χ12=0.4 -- 55.0 52.6 χ12=0.0 -- 9.1 10.0 χ12=0.0 -- 
No 85.5 87.1 χ12=0.3 p=0.52 59.2 45.8 χ12=7.3 p=0.73 86.8 93.1 χ12=5.2 p=0.05 52.9 47.5 χ12=1.3 p=0.35 53.6 53.2 χ12=0.0 p=0.91 25.4 13.7 χ12=5.4 p=0.57 
1. Interaction term between treatment dummy and each variable.  





Appendix Table 4.1. Number and percentage of cases with missing values for 




 TEDS-A, 2012 NSDUH, 2013-14 CTO0001 MDS0004 CTN0052 CTO0005 
 Target  Target  RCT RCT RCT RCT 
Total Valid N 32,287 235 115 209 62 65 
Total Missing N 4,710 0 4 1 0 0 
% Total Missing 12.7 0.0 3.3 0.5 0.0 0.0 
Sex       
Valid N 36,919 235 119 210 62 65 
Missing N 78 0 0 0 0 0 
% Missing  0.2 0.0 0.0 0.0 0.0 0.0 
Race       
Valid N 36,734 235 117 209 62 65 
Missing N 263 0 2 1 0 0 
% Missing  0.7 0.0 1.7 0.5 0.0 0.0 
Age       
Valid N 36,997 235 119 210 62 65 
Missing N 0 0 0 0 0 0 
% Missing  0.0 0.0 0.0 0.0 0.0 0.0 
Education        
Valid N 36,281 235 119 210 62 65 
Missing N 716 0 0 0 0 0 
% Missing  0.2 0.0 0.0 0.0 0.0 0.0 
Employment       
Valid N 35,965 235 119 210 62 65 
Missing N 1,032 0 0 0 0 0 
% Missing  2.8 0.0 0.0 0.0 0.0 0.0 
Marital Status       
Valid N 34,428 235 118 210 62 65 
Missing N 2,569 0 1 0 0 0 
% Missing  6.9 0.0 0.8 0.0 0.0 0.0 
IV drug use        
Valid N 36,328 235 119 210 62 65 
Missing N 669 0 0 0 0 0 
% Missing  0.2 0.0 0.0 0.0 0.0 0.0 
Number of prior treatments       
Valid N 35,800 235 118 210 62 65 
Missing N 1,197 0 1 0 0 0 
% Missing  0.3 0.0 0.8 0.0 0.0 0.0 
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Appendix Table 4.2. Results of subgroup analysis of treatment effects 
  Retention (end of trial) Abstinence  (end of trial) 
  T C Test Interaction T C Test Interaction 
Study (Treatment) Variable          
Overall Sex         
 Men  69.2 63.6 χ12=1.1 -- 22.3 23.2 t=0.8 -- 
 Women  71.6 67.9 χ12=0.2 p=0.87 21.3 22.0 t=0.4 p=0.91 
 Race         
 White 65.9 54.8 χ12=1.5 -- 22.6 25.0 t=1.3 -- 
 Non-White 71.4 68.5 χ12=0.3 p=0.48 21.8 22.3 t=0.4 p=0.37 
 Age         
 < 35 59.7 43.3 χ12=2.1 -- 20.2 23.2 t=1.1 -- 
 ≥ 35 72.4 69.4 χ12=0.4 p=0.32 22.5 22.8 t=0.3 p=0.33 
 Education         
 < 12 years 75.0 73.1 χ12=0.0 -- 21.2 24.6 t=1.5 -- 
 ≥ 12 years 68.8 63.5 χ12=1.1 p=0.82 22.3 22.5 t=0.2 p=0.19 
 Employment          
 Full-time 58.8 48.1 χ12=1.6 -- 22.7 22.7 t=-0.0 -- 
 Other 76.1 72.1 χ12=0.6 p=0.60 21.8 22.9 t=1.0 p=0.61 
 Marital status         
 Married 56.3 69.1 χ12=1.8 -- 22.4 22.4 t=-0.0 -- 
 Non-married 73.7 63.6 χ12=4.0 p=0.03 22.1 23.0 t=0.9 p=0.66 
 IV drug use          
 Yes 76.5 66.7 χ12=0.4 -- 18.7 19.8 t=0.3 -- 
 No 69.0 64.9 χ12=0.8 p=0.72 22.6 23.1 t=0.5 p=0.86 
 Prior 
treatment  
        
 Yes  76.7 68.2 χ12=2.4 -- 21.7 23.1 t=1.1 -- 
 No 60.5 58.7 χ12=0.1 p=0.40 22.7 22.5 t=-0.1 p=0.46 
          
CTO0001 (Reserpine)          
 Sex         
 Men  67.4 68.3 χ12=0.0 -- 20.6 23.2 t=1.3 -- 
 Women  64.7 55.6 χ12=0.3 p=0.61 16.8 19.1 t=0.6 p=0.92 
 Race         
 White 61.1 44.4 χ12=0.7 -- 20.6 29.5 t=1.3 -- 
 Non-White 69.3 69.4 χ12=0.0 p=0.47 18.9 21.8 t=1.4 p=0.36 
 Age         
 < 35 66.7 46.7 χ12=1.1 -- 11.4 20.7 t=2.1 -- 
 ≥ 35 66.7 70.5 χ12=0.2 p=0.28 21.6 22.5 t=0.5 p=0.05 
 Education         
 < 12 years 62.5 70.0 χ12=0.1 -- 22.2 22.1 t=0.0 -- 
 ≥ 12 years 67.3 63.3 χ12=0.2 p=0.64 19.2 22.2 t=1.5 p=0.56 
 Employment          
 Full-time 54.6 66.7 χ12=0.5 -- 18.2 25.0 t=2.3 -- 
 Other 73.7 63.6 χ12=1.0 p=0.25 20.1 21.2 t=0.5 p=0.15 
 Marital status         
 Married 46.2 70.0 χ12=1.3 -- 17.5 22.3 t=1.1 -- 
 Non-married 71.7 63.3 χ12=0.8 p=0.16 20.1 22.2 t=1.0 p=0.59 
 IV drug use          
 Yes 100.0 80.0 χ12=0.7 -- 25.0 17.8 t = -
1.2 
-- 
 No 64.9 63.0 χ12=0.0 --1 19.1 22.7 t=1.9 p=0.10 
 Prior 
treatment  
        
 Yes  67.7 67.6 χ12=0.0 -- 19.5 23.3 t=1.7 -- 
 No 65.5 57.1 χ12=0.4 p=0.67 19.6 20.2 t=0.2 p=0.39 
MDS0004 (Modafinil)          
 Sex         
 Men  69.0 58.8 χ12=1.5 -- 22.9 22.0 t = -
0.6 
-- 
 Women  76.3 71.4 χ12=0.2 p=0.79 21.2 19.8 t = -
0.5 
p=0.89 
 Race         
 White 73.0 62.5 χ12=0.7 -- 23.7 23.2 t = -
0.2 
-- 
 Non-White 70.3 61.7 χ12=1.1 p=0.88 21.9 20.2 t = -
1.0 
p=0.70 
 Age         
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 < 35 59.1 50.0 χ12=0.2 -- 20.3 24.8 t=0.9 -- 
 ≥ 35 73.3 64.1 χ12=1.7 p=0.94 22.7 20.9 t = -
1.2 
p=0.19 
 Education         
 < 12 years 76.5 60.0 χ12=0.5 -- 20.6 25.7 t=1.1 -- 
 ≥ 12 years 70.3 62.7 χ12=1.1 p=0.70 22.7 21.0 t = -
1.2 
p=0.20 
 Employment          
 Full-time 62.2 47.8 χ12=1.3 -- 22.1 21.3 t = -
0.5 
-- 
 Other 75.3 69.4 χ12=0.6 p=0.66 23.3 21.2 t = -
0.7 
p=0.68 
 Marital status         
 Married 70.6 76.2 χ12=0.2 -- 23.3 23.7 t=0.2 -- 
 Non-married 71.2 56.9 χ12=3.1 p=0.21 22.1 19.9 t = -
1.2 
p=0.40 
 IV drug use          
 Yes 80.0 33.3 χ12=2.7 -- 15.2 18.0 --9 -- 





        
 Yes 79.3 63.4 χ12=3.6 -- 21.7 19.2 t = -
1.3 
-- 
 No 58.9 61.3 χ12=0.0 p=0.15 23.7 24.1 t=0.2 p=0.32 
CTN0052 (Buspirone)          
 Sex         
 Men  95.8 80.0 χ12=2.5 -- 24.0 26.3 t=0.9 -- 
 Women  81.8 91.7 χ12=0.5 p=0.14 26.7 27.6 t=0.5 p=0.72 
 Race         
 White 88.9 71.4 χ12=0.8 -- 21.4 28.2 t=1.5 -- 
 Non-White 92.3 90.0 χ12=0.1 p=0.61 25.9 26.6 t=0.4 p=0.13 
 Age         
 < 35 100.0 0.0 χ12=4.0 -- 29.3 --10 --10 -- 
 ≥ 35 90.6 88.5 χ12=0.1 --2 24.3 26.9 t=1.5 --10 
 Education         
 < 12 years 92.9 100.0 χ12=0.6 -- 23.5 29.0 t=2.4 -- 
 ≥ 12 years 90.5 79.0 χ12=1.0 --3 25.6 25.8 t=0.1 p=0.13 
 Employment          
 Full-time 85.7 33.3 χ12=3.7 -- 29.0 26.5 t = -
1.3 
-- 
 Other 92.8 100.0 χ12=1.6 --4 23.8 27.0 t=1.7 p=0.29 
 Marital status         
 Married 66.7 60.0 χ12=0.0 -- 16.5 20.7 t=1.0 -- 
 Non-married 93.8 90.9 χ12=0.2 p=0.95 25.3 27.9 t=1.5 p=0.78 
 IV drug use          
 Yes 100.0 100.0 --5 -- 27.5 30.0 --9 -- 
 No 90.9 84.6 χ12=0.6 --5 24.6 26.8 t=1.2 p=0.97 
 Prior 
treatment  
        
 Yes 91.4 85.2 χ12=0.6 -- 24.8 26.9 t=1.3 -- 
 No --6 --6 --6 --6 --6 --6 --6 --6 
CTO0005 
(Ondansetron) 
         
 Sex         
 Men  56.1 50.0 χ12=0.2 -- 21.2 23.3 t=0.5 -- 
 Women  50.0 0.0 χ12=1.7 --7 23.0 --10 --10 --10 
 Race         
 White 47.6 25.0 χ12=0.7 -- 22.3 28.0 --9 -- 
 Non-White 60.7 50.0 χ12=0.4 p=0.69 20.9 22.5 t=0.4 p=0.69 
 Age         
 < 35 58.6 50.0 χ12=0.2 -- 24.4 29.0 t=1.4 -- 
 ≥ 35 50.0 33.3 χ12=0.5 p=0.78 19.7 21.0 t=0.2 p=0.68 
 Education         
 < 12 years 55.0 46.2 χ12=0.3 -- 15.8 4.0 --9 -- 
 ≥ 12 years 55.6 33.3 χ12=0.4 p=0.72 22.7 26.5 t=1.1 p=0.10 
 Employment          
 Full-time 50.0 25.0 χ12=1.6 -- 19.9 26.3 t=1.4 -- 
 Other 61.9 62.5 χ12=0.0 p=0.72 22.9 16.0 t = -
1.0 
p=0.10 
 Marital status         
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 Married 28.6 50.0 χ12=0.8 -- 27.5 17.3 t = -
1.7 
-- 
 Non-married 65.7 40.0 χ12=2.1 p=0.11 20.4 27.8 t=1.6 p=0.03 
 IV drug use          
 Yes --8 64.3 --8 -- 19.4 --10 --10 -- 
 No 51.3 43.8 χ12=0.3 --8 22.4 23.3 t=0.2 --10 
 Prior 
treatment  
        
 Yes 52.6 20.0 χ12=1.7 -- 16.9 28.0 --9 -- 
 No 58.6 54.6 χ12=0.1 p=0.35 24.1 22.5 t = -
0.5 
p=0.19 
1: All the participants who had IV drug use in the treatment arm successfully retained in the study and it was not possible to estimate a coefficient for interaction 
term.  
2: All the participants aged <35 years old in the treatment arm successfully retained in the study and it was not possible to estimate a coefficient for interaction 
term.  
3: All the participants with less than 12 years of education in the control arm successfully retained in the study and it was not possible to estimate a coefficient for 
interaction term.  
4: All the participants without fulltime job in the control arm successfully retained in the study and it was not possible to estimate a coefficient for interaction term. 
5: All the participants who had IV drug use successfully retained in the study and it was not possible to calculate chi-squared statistics and to estimate a coefficient 
for interaction term. 
6: There was no observation of those who had no prior treatments.  
7: No female participants in the control arm successfully retained in the study and it was not possible to estimate a coefficient for interaction term.  
8: All the participants who had IV drug use were in the treatment arm and it was not possible to calculate chi-squared statistics and to estimate a coefficient for 
interaction term. 
9: There was only one observation in the control arm and it was not possible to calculate t-statistics. 
10: There was no observation in the control arm and it was not possible to calculate t-statistics and to estimate a coefficient for interaction term. 
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Appendix Table 4.3. Comparison of propensity scores between the RCT samples and target samples from the 
Treatment Episodes Data-Admission (TEDS-A) and the National Survey of Drug Use and Health (NSDUH). 
Target population = TEDS-A 
Study number  Intervention RCT TEDS-A pa Pooled standard deviation  Standard pb t-Test P-value 
CTO0001 Reserpine 0.64 0.25 0.39 0.21 1.86 20.41 <0.001 
MDS0004 Modafinil 0.60 0.24 0.36 0.22 1.61 23.44 <0.001 
CTN0052 Buspirone 0.66 0.24 0.42 0.22 1.94 15.30 <0.001 
CTO0005 Ondansetron 0.73 0.17 0.56 0.19 3.01 24.44 <0.001 
Target population = NSDUH 
Study number  Intervention RCT NSDUH p Pooled standard deviation  Standard p t-Test P-value 
CTO0001 Reserpine 0.73 0.24 0.49 0.35 1.40 16.61 <0.001 
MDS0004 Modafinil 0.74 0.31 0.43 0.36 1.22 16.25 <0.001 
CTN0052 Buspirone 0.80 0.23 0.57 0.34 1.68 16.05 <0.001 
CTO0005 Ondansetron 0.61 0.31 0.30 0.25 1.20 9.86 <0.001 
a Δp is difference between propensity scores of the RCT sample and the target population.  







Appendix Figure 4.1. Density plots of propensity scores in RCT samples and target sample from the Treatment 







Appendix Figure 4.2. Density plots of propensity scores in RCT samples and target sample from the National 
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